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ABSTRACT
Background: The contemporary management of ambulatory ulcerative
colitis (UC) continues to be challenging with 20% of children needing
a colectomy within childhood years. We thus aimed to standardize daily
treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclas-
sified through detailed recommendations and practice points.
Methods: These guidelines are a joint effort of the European Crohn’s and
Colitis Organization (ECCO) and the Paediatric IBD Porto group of European
Society of Paediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN). An extensive literature search with subsequent evidence
appraisal using robust methodology was performed before 2 face-to-face
meetings. All 40 included recommendations and 86 practice points were
endorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate.
Results: These guidelines discuss how to optimize the use of mesalamine
(including topical), systemic and locally active steroids, thiopurines and, for
more severe disease, biologics. The use of other emerging therapies and the
role of surgery are also covered. Algorithms are provided to aid therapeutic
decision-making based on clinical assessment and the Paediatric UC Activity
Index (PUCAI). Advice on contemporary therapeutic targets incorporating
the use of calprotectin and the role of therapeutic drug monitoring are
presented, as well as other management considerations around pouchitis,
extraintestinal manifestations, nutrition, growth, psychology, and transition.
A brief section on disease classification using the PIBD-classes criteria and
IBD-unclassified is also part of these guidelines.
Conclusions: These guidelines provide a guide to clinicians managing children
with UC and IBD-unclassified management to provide modern management stra-
tegies while maintaining vigilance around appropriate outcomes and safety issues.
Key Words: anti-TNF, calprotectin, children, guidelines, inflammatory
bowel disease-unclassified, management, mesalamine, monitoring,
pediatrics, Pediatric Ulcerative Colitis Activity Index, thiopurines,
treatment, ulcerative colitis, vedolizumab
(JPGN 2018;67: 257–291)
What Is Known
 The previously published European Society of Paedi-
atric Gastroenterology, Hepatology and Nutrition–
European Crohn’s and Colitis Organization guide-
lines were published in 2012 and are updated
herein.
What Is New
 The diagnosis section has been replaced by the
inflammatory bowel disease-classes criteria; a discus-
sion of inflammatory bowel disease-unclassified has
been added; fecal calprotectin has been given more
emphasis; new drugs (eg, vedolizumab, golimumab)
have been incorporated as off-label medications;
recommendations for therapeutic drug monitoring
have been provided; a treat to target algorithm has
been added and other sections updated.
INTRODUCTION
U lcerative colitis (UC) is a disease with a less heterogeneousphenotype than Crohn disease (CD) but it still poses many
unique challenges. The incidence of pediatric onset UC, which
constitutes roughly 15% to 20% of all UC, ranges at 1 to 4/100,000/
year in most North American and European regions (1). It is
extensive in 60% to 80% of all cases, twice as often as in adults
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(2). Since disease extent has been consistently associated with
disease severity, it is not surprising that children with UC more
often require hospitalization for an acute severe exacerbation
(25%–30% over 3–4 years) (3,4) and more often undergo colect-
omy for medically refractory disease (up to 30%–40% in 10-year
follow-up (2,5), although lower colectomy rates have also been
reported (6–8)). Canadian population-based health administrative
data showed no reduction of colectomy rate from 1994 to 2007
before the widespread use of biologics (9). In addition to more
severe colitis, children also have unique age-related issues, such as
growth, pubertal development, nutrition, and bone mineral density
accretion, as well as differing psychosocial needs. Finally, although
mortality in pediatric UC has become rare, a retrospective case
collection across Europe over 6 years reported 19 deaths in children
with UC mainly due to infections and cancer (1 case of colorectal
cancer [CRC]), including 1 with toxic megacolon (10).
The revised Porto criteria (11) proposed explicit guidance for
diagnostic workup in pediatric inflammatory bowel diseases
(IBDs). Consequently, the Paediatric IBD Porto group of European
Society of Paediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN) published the ‘‘PIBD-Classes’’ criteria that standard-
ized the differentiation of pediatric IBD into 5 categories: typical
UC, atypical UC, IBD-unclassified (IBDU), Crohn colitis and CD
(12); the first 3 categories will be covered in these guidelines.
The PIBD-classes system is based on 23 features that are
typical of CD, grouped in 3 classes: those that are totally incompatible
with UC and thus should be diagnosed as CD; those that may be
present in UC but rarely (<5%; class 2); and those that may be present
in UC uncommonly (5%–10%; class 3). Accumulation of the differ-
ent features, weighted by the classes, standardized the diagnosis of
PIBD (Fig. 1, Table 1). The sensitivity and specificity of the PIBD-
classes to differentiate UC from CD and IBDU was 80% and 84%,
and CD from IBDU and UC 78% and 94%, respectively (12).
The use of the Paris classification is advocated for phenotyp-
ing pediatric UC, with E1-E4, A1a-A2, and S0-S1 denoting disease
extent, age of diagnosis and severity, respectively (13). Additional
labels of very-early onset IBD (6 years of age at diagnosis) and
infantile IBD (<2 years of age) may also be added (14).
We aimed to develop guidelines for managing UC in children
based on a systematic review of the literature and a robust consensus
process of an international working group composed of specialists
in pediatric IBD from the ESPGHAN and the European Crohn’s and
Colitis Organization (ECCO). We focus on the principles, pitfalls,
and pediatric considerations related to the diagnosis and care of
children and adolescents with UC. These guidelines supplement
those published for adults (15,16); similar topics are covered only in
brief, referencing the extensive ECCO review. The pediatric UC
guidelines are divided into 2 parts but should be read as 1 manu-
script: Part 1: ambulatory UC (updating the previous 2012 ECCO-
ESPGHAN guidelines (17)) and Part 2: acute severe colitis (ASC;
updating the previous 2011 ECCO-ESPGHAN guidelines (18)).
In addition to providing an update of new literature, several
major topics have changed from the previous guidelines. The
diagnosis section has been replaced by the aforementioned IBD-
Classes criteria; a discussion of IBDU has been added; fecal
calprotectin has been given more emphasis; new drugs (eg, vedo-
lizumab, golimumab, and locally active steroids) have been incor-
porated as off-label medications; practical recommendations for
therapeutic drug monitoring have been provided; the use of throm-
botic prophylaxis has been revisited based on predicting variables;
sequential therapy has been newly presented; a treat to target
algorithm has been added; and other sections updated and changed.
METHODS
Following an open call in ECCO and the Porto plus the
Interest Paediatric IBD groups of ESPGHAN, 22 international
experts in pediatric IBD were selected by the steering committee,
including 2 pediatric surgeons. A list of 23 questions addressing the
management of UC in children was first developed (composing the
subtitles of the current manuscript and the next one on ASC). Next,
a systematic review of the literature was performed centrally by 2 of
the authors (E.O.M. and C.S.) with the aid of an experienced
librarian searching for all combinations of UC and pediatrics
(Supplemental Table 1, Supplemental Digital Content 1, http://
links.lww.com/MPG/B393). Electronic searches were performed in
Oct 2016 using Medline, Embase, and web of science. Clinical
guidelines, systematic reviews, clinical trials, cohort studies, case-
control studies, diagnostic studies, surveys, letters, narrative
reviews, case series, and highly relevant selected abstracts
published after 1985 were all utilized if performed in children.
Following elimination of duplicates, 10,096 abstracts were
reviewed by EOM for eligibility. A total of 8,996 abstracts were
excluded, mainly for the following reasons: clear irrelevance to
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the pre-defined topics, manuscripts published before 1985, review
manuscripts, manuscripts focusing on CD, or on molecular/genetic
pathways. Although we aimed to base our adult literature on the
recently updated ECCO UC guidelines (15,16), salient adult RCTs
identified in the initial search were not excluded for perusal and
reference. The decision regarding questionable eligibility was made
by one of the senior authors (D.T.). Finally, 1100 full-text manu-
scripts were retrieved and circulated to the relevant subgroups for
writing their sections. Highly relevant manuscripts published after
the search date were included individually.
Each of the 23 questions was allocated to a subgroup of 2
experts for drafting of the first text. The subgroup’s text and
recommendations were iterated by e-mail with the steering com-
mittee until refined. The guidelines include both recommendations
and practice points that reflect common practice where evidence is
lacking or provide useful technical details, including grading of
0
0
0
UC
1-2
UC 
atypical
3-5
IBDU
1-3
0-2
IBDU
3-5
CD 
colonic
4-12
CD 
colonic
1-6
CD
# Class 1
features
# Class 2
features
# Class 3
features
FIGURE 1. Classification algorithm into paediatric inflammatory bowel disease (IBD) subclasses based on the ‘‘PIBD-classes’’ features of Table 1
(reproduced from reference 12).
TABLE 1. PIBD-classes features
Q Feature
Class 1 1 At least 1 well-formed granuloma anywhere in the gastrointestinal tract, remote from ruptured crypt
2 At least one of deep ulcerations, cobblestoning or stenosis anywhere in the small bowel or upper gastrointestinal tract (excluding
stomach)

3 Fistulizing disease (internal or perianal)
4 Large inflamed perianal skin tags
5 Thickened jejunal or ileal bowel loops on radiology or other evidence of significant small bowel inflammation on capsule endoscopy not
compatible with backwash ileitis
6 Any ileal inflammation in the presence of normal cecum (ie, incompatible with backwash ileitis)y
Class 2 7 Macroscopically and microscopically normal appearing skip lesions in untreated patients (excluding rectal sparing and cecal patch)
8 Complete (macroscopic and microscopic) rectal sparing
9 Macroscopically normal colon in between inflamed mucosa but with microscopic inflammation (ie, relative patchiness)
10 Significant growth delay (height velocity<minus 2 SD), not explained by other causes (eg, celiac disease, prolonged steroid treatment or
growth hormone deficiency)
11 Transmural inflammation of the colon in the absence of severe colitis
12 Small and not deep ulcers (including aphthous ulcerations), anywhere in the small bowel, duodenal and esophageal (excluding stomach
and colon) not explained by other causes (eg, Helicobacter pylori, NSAIDS and celiac disease)z
13 Multiple (5) small and not deep ulcers (including aphthous ulcerations), in the stomach or colon (on the background of normal mucosa),
not explained by other causes (eg, H pylori and NSAIDs)
14 Ileitis, otherwise compatible with backwash ileitis,§ but in the presence of only mild inflammation in the cecum
15 Positive ASCA in the presence of negative pANCA
16 Reverse gradient of mucosal inflammation (proximal > distal (except rectal sparing))
17 Severe scalloping of the stomach or duodenum, not explained by other causes (eg, celiac disease and H pylori)
18 Deep ulcerations (at least 1) or severe cobblestoning of stomach not explained by other causes (eg, H pylori, NSAIDs and celiac disease)
Class 3 19 Focal chronic duodenitis on histology
20 Focal active colitis on histology in >1 biopsy
21 Several (<5) aphthous ulcerations in the colon or in the stomach
22 Non-bloody diarrhoea
23 Focal enhanced gastritis on histology
To be used in the PIBD-classes algorithm (Fig. 1). Reproduced from reference 12.
Deep ulcerations or severe cobblestoning of stomach score as item #18; if there are ulcerations in the duodenum or oesophagus, which are small and not
deep, score as item #12.
yIf cecum with mild inflammation score as item #14.
zIf ulcers are deep score as item #2.
§Backwash ileitis: a short segment of non-stenotic erythema or edema in the presence of pancolitis including the ileocecal valve, without granulomata or deep
ulcers.
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evidence according to the Newcastle-Ottawa assessment scales for
case-control and cohort studies (19) and according to the Cochrane
Handbook for clinical trials (20) (Supplemental Table 2: tables of
evidence with grading, Supplemental Digital Content 2, http://
links.lww.com/MPG/B394). The group then voted on all recom-
mendations and practice points while adding specific comments
using a web-based voting platform. A second round of electronic
voting and revisions was done, including all members of the
Paediatric IBD Porto group of ESPGHAN. In addition, the draft
was circulated for comments to ECCO (national representatives and
governing board) and to members of the IBD Interest group
of ESPGHAN.
The group met twice face-to-face: during UEGW annual
meeting (Barcelona, October 2016) before drafting the initial
topics and during ESPGHAN annual meeting (Prague,
May 2017) after the 2 voting rounds were completed. Themeetings
were supplemented by an e-mail Delphi process with the entire
group until agreement was reached. In total 43 pediatric IBD
experts voted on all recommendations and practice points: 35
Porto group members (of whom 14 were authors) and 8 non-Porto
group authors (Supplemental Table 3: names of the 43 voting
experts, Supplemental Digital Content 1, http://links.lww.com/
MPG/B393). All statements and practice points were supported
by at least 88% of the group. Recommendations were graded
according to Oxford Centre for Evidence-Based Medicine (see
table at https://www.cebm.net/wp-content/uploads/2014/06/
CEBM-Levels-of-Evidence-2.1.pdf (21)).
EVALUATION AND PREDICTION
Assessing and Predicting Disease Activity
Recommendations
1. Disease activity should be monitored at every visit
utilizing the PUCAI [EL2] and treatment should be
revisited when PUCAI  10 points [EL2]. (93%
agreement) (Fig. 2)
2. Colonoscopic evaluation is recommended at diag-
nosis [EL4, adults EL4], before major therapeutic
modifications [EL5, adults EL5], for cancer surveil-
lance [EL5, adults EL3], and when it is not clear if
symptoms are disease-related especially if calprotec-
tin is elevated [EL5, adults EL5]; it is not routinely
indicated during relapses that are not severe [EL5,
adults EL5]. (100% agreement)
3. If available, fecal calprotectin should be obtained
while in sustained clinical remission and endoscopic
evaluation should be considered when calprotectin
is high, as defined below and in Figure 2 [EL2, adults
EL2]. (88% agreement)
Practice Points
1. Clinical remission is defined as PUCAI < 10 points,
mild disease as 10 to 34 points, moderate disease
35 to 64 points and severe disease 65 points
(Appendix 1). Clinically significant response is
defined by a PUCAI change of at least 20 points,
or entering remission. (95% agreement)
2. Long-term prognosis is better in patients who
achieve complete clinical remission (ie, PUCAI
< 10) during the first 3 months after diagnosis.
(95% agreement)
3. There is currently no evidence whether measuring
calprotectin in a child who is in a PUCAI-defined
remission has an added value for predicting disease
course. Given the fact that significant endoscopic
disease may, however, be present in 20% of chil-
dren with PUCAI < 10, it is reasonable to measure
calprotectin once sustained clinical remission has
been achieved to verify mucosal healing and select
those who require endoscopic assessment. Other
fecal markers (eg, lactoferrin) may have a compara-
ble diagnostic value, but less supportive data are
available. (93% agreement)
4. There is no ideal cutoff value of fecal calprotectin to
reflect mucosal inflammation and predict disease
outcome (Tables 2 and 3). Values differ substantially
in the different studies using different reference
standards. Cutoff value <100 mg/g usually reflects
remission while >250mg/g more accurately pre-
dicts mucosal inflammation. The value that should
trigger an endoscopic evaluation or a change in
treatment should be thus individualized based on
these values, especially when values increase over
time. (98% agreement)
5. An episode of acute severe colitis (ie, PUCAI  65) is
a risk factor for a more aggressive disease course and
thus this should be incorporated in the manage-
ment scheme. (100% agreement)
6. Blood tests (CBC, albumin, transaminases, gGT, CRP,
and ESR) should be performed regularly depending
onsymptomsandtherapyandat leastevery3months
while on immunosuppressive medications and at
least every 6 to 12 months otherwise. It is a common
practice to include testing for renal function in
patients taking mesalamine and annual urinalysis;
however, there is no evidence that this prevents
adverse outcomes. (98% agreement)
7. Before treatment modification, it is essential to con-
sider other clinical conditions such as non-adher-
ence, irritable bowel syndrome, celiac disease,
medication-related adverse events, and infections
(especially Clostridium difficile, which should be
excluded in any acute exacerbation, but also bacte-
rial infections and CMV). (95% agreement)
8. A standardized endoscopic activity index, including
the Mayo endoscopic subscore or Ulcerative Colitis
Endoscopic Index of Severity (UCEIS), should be
used during colonoscopic examinations. (95%
agreement)
9. CRC surveillance by a trained endoscopist is recom-
mended following 8 to 10 years of disease duration,
dictated by risk factors such as disease extent, dis-
ease severity over the course of disease and family
history. Surveillance recommendations in children
with primary sclerosing cholangitis (PSC) can be
found in the PSC section. According to the adult
guidelines, chromoendoscopy with targeted biop-
sies has been shown to increase dysplasia detection
rate. If not available, random biopsies (quadrantic-
biopsies every 10 cm) and targeted biopsies of any
visible lesion should be performed using high defi-
nition endoscopes. (93% agreement)
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In 2 pediatric inception cohorts, disease severity during the
first 3 months after diagnosis and the occurrence of an episode of
ASC were associated with increased risk of refractory disease
(22,23). Thus, by using constructs of disease severity it is possible
to characterize children who are at high risk for a more complicated
disease course and to guide management and tight monitoring.
Endoscopy is the reference standard to evaluate mucosal
inflammation. Mayo endoscopic score of none, mild, moderate, or
severe (0–3 points) with number of involved colonic segments
(rectum, sigmoid, and descending, transverse, and ascending colon)
may be used in pediatric UC (24). The modified Mayo endoscopic
score is an easy to use, non-validated tool, which combines disease
extent with Mayo Endoscopic score (25). The Ulcerative Colitis
Endoscopic Index of Severity (UCEIS) is a convenient and vali-
dated index which includes vascular pattern, bleeding, and ulcers at
the worst part (26,27). These indices are described in the coming
ESPGHAN Porto group guidelines of endoscopy utilization in IBD
(JPGN 2018).
Mucosal healing in UC is associated with a favorable disease
outcome in adult patients (28–31). Nevertheless, clinical remission
has been proven to predict long-term outcomes in UC, with no less
accuracy than endoscopic evaluation, both in children using the
PUCAI (23,32) and in adults (33). An adult study showed that
UCEIS predicted relapse in 155 patients who were in clinical
remission; however, clinical remission was not stringently defined
(ie, partial Mayo score of 0–1, allowing for streaks of blood for
instance) and the number needed to test was high (34). A post-hoc
analysis of the adult ACT trials showed that while endoscopic
inflammation predicted colectomy, this was not the case in the
subgroup of patients who were in clinical remission (28). A PUCAI-
TABLE 2. The utility of different cutoff values of faecal calprotectin to predict endoscopic disease in UC (selected references)
Study design Cutoff Reference standard Sens Spec PPV NPV
Paediatric
Diamanti (60) n¼ 41; retrospective 275 Histology 94 95 94 95
Adult
D’Haens (471) n¼ 39; prospective 250 Endoscopic Mayo > 0 71 100 100 47
Endoscopic Mayo > 1 86 78 82 82
Schoepfer (472) n¼ 228; prospective 57 Modified Baron  2 91 90
50 Modified Baron  2 92 86
Scaioli (473) n¼ 121; prospective 110 Endoscopic Mayo > 0 98 90 93 98
270 Endoscopic Mayo > 1 88 88 88 93
Dranga (474) n¼ 103; prospective 15 Endoscopic Mayo > 0 98 76 96 46
Langhorst (475) n¼ 42; prospective 48 Endoscopy total score > 1 81 72
Falvey (476) n¼ 65; prospective 125 Baron score > 1 74 80 85 67
Guardiola (477) n¼ 59; prospective 155 Endoscopic Mayo¼ 0–1 and activity on histology 89 71 54 89
Lin (478) n¼ 52; prospective 191 UCEIS < 3 88 75
Lobato´n (479) n¼ 123; prospective 250 Endoscopic Mayo ¼ 0–1 73 89 86 79
160 Endoscopic Mayo ¼ 0 66 85
Samant (480) n¼ 32; retrospective 800 Endoscopic Mayo > 1 96 71
Xiang (481) n¼ 66; prospective 50 Sutherland criteria > 2 91 79
Nancey (482) n¼ 55; prospective 250 Rachmilewitz  2 91 87 87 91
100 100 53 85 100
Takashima (483) n¼ 92; prospective 250 Endoscopic Mayo ¼ 0 82 62 61 83
200 77 72 67 81
369 Endoscopic Mayo ¼ 0–1 86 63 79 74
250 70 66 76 59
Sandborn (484) n¼ 194; prospective 150 Mayo score 2, with no subscore >1 68 79 57 86
Endoscopic Mayo ¼ 0 79 75 39 94
Endoscopic Mayo ¼ 0–1 85 54
NPV¼Negative Predictive Value; PPV¼Positive Predictive Value.
Fecal calprotecn4
1. Ensure compliance
2. Exclude infecons, medicaons side eﬀects 
and other diagnoses 
3. Escalate, opmise and combine therapies 
Maintenance therapy with 5-ASA and/or thiopurines and/or biologics
PUCAI score
PUCAI≥10 or steroid-dependent
Endoscopic 
evaluaon
PUCAI<10
FC>2503
1. Monitor PUCAI periodically
2. Monitor calprotecn periodically
3. Surveillance colonoscopy following 
8-10 years of disease (see text)
Colis (Mayo>0/1)2 Mucosal healing
FC<100
Repeat calprotecn 
and frequent FU
FC 100-250
Aer 3 months1
FIGURE 2. Algorithm for monitoring paediatric ulcerative colitis (UC)
during the maintenance phase. (1) Assessments earlier than 3 months
are usually required and in any significant disease or deterioration,
early intervention is required. (2) The decision whether to escalate
therapy based on a Mayo—0 or 1 endoscopic findings should be
individualized such as based on the current treatment (eg, it is easier to
increase mesalamine dose or add rectal therapy than starting thiopur-
ines), symptoms and extent (short Mayo 1 segment may be closely
monitored whereas extensive disease may require escalation). (3)
Proceeding to colonoscopy should preferably be based on at least
2 independent measurements of calprotectin. (4) Obtaining calpro-
tectin may be delayed to 4 to 6 months since histological remission
lags after macroscopic improvement.
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defined remission at 3 months following diagnosis predicted 1-year
sustained steroid-free remission (AUROC 0.7, 95% CI 0.6–0.8) and
colectomy by 2 years (AUROC 0.75, 0.6–0.89). It was superior to
both CRP and ESR (23) and predicted choice of treatment (35,36).
Furthermore, in the prospective multicenter PROTECT pediatric
cohort study, failure to achieve clinical remission (PUCAI < 10)
4 weeks after discharge of children who required intravenous
corticosteroids at disease onset was highly associated with need
for additional medical therapy by week 12 (37).
PUCAI cutoff scores of remission, mild, moderate, and
severe disease have been validated in several cohorts (35,38,39)
and were successfully utilized in the PROTECT study to guide the
choice of initial treatment at disease onset, as outlined in Figure 3
(37). PUCAI at diagnosis was associated with steroid-free remission
rates at week 12 and with long-term outcomes (at 54 weeks).
Selected children with moderate disease activity were, however,
treated with 5-aminoscalicylic acid (5-ASA) and not with oral
steroids, and on average had similar outcomes at week 12; this
supports our algorithm that 5-ASA may be considered also in the
lower range of the moderate disease activity group (Fig. 3). The
PUCAI correlates well with endoscopic appearance of the colonic
mucosa, showing similar remission rates in multiple studies (38–
43). In addition, the correlation of the PUCAI with Mayo score has
been reported to be as high as 0.95 (32,38,39). While most
aforementioned studies report a group average, on an individual
basis there is a likelihood of 20% for a significant mucosal
inflammation even in the presence of a PUCAI-defined complete
remission (44). Therefore, biomarkers should be used to confirm
endoscopic remission in those who are in sustained clinical remis-
sion, particularly in the presence of PSC where the PUCAI does not
correlate well with mucosal inflammation (45) (Fig. 2).
Routine laboratory parameters (platelets, CRP, albumin,
hemoglobin) are more frequently normal in UC than in CD during
mild to moderate flares (46,47). In contrast to adult UC, high
sensitivity (hs)-CRP was not suitable to differentiate between remis-
sion and relapse in children with normal standard CRP (48). In
TABLE 3. Cutoff values of faecal calprotectin in prediction poor outcome in ulcerative colitis (selected references)
Study design Sampling time Reference outcome Cutoff Follow-up Sens Spec PPV NPV
De Vos (486) n¼ 113; pro Clinical remission with
infliximab
Relapse: change in therapy
or endoscopic Mayo> 2
>300 52 weeks 93 58 — —
Gisbert (487) n¼ 74; pro Clinical remission for 6
months
Remission <150 12 months 31 91 — —
<167 69 74 — —
Ho (488) 90; pro Acute severe colitis Colectomy >1922 24 97 — —
>431 96 20 — —
Lasson (489) n¼ 69; pro At diagnosis Mayo score < 3 <169 12 months 64 70 80 51
<262 24 months 51 81 85 45
<262 36 months 52 85 88 45
Costa (490) n¼ 41; pro Clinical remission for 1–
12 months
Remission; (UCAI < 5) <150 12 months 89 82 81 90
D’Inca (491) n¼ 97; pro Remission Remission; (Edwards and
Truelove score < 3)
<130 12 months 70 70 — —
Garcia-Sanchez
(492)
n¼ 69; pro Clinical remission for
3 months
Remission; (modified
Truelove and Witts
< 11)
<120 12 months 81 63 49 88
Yamamoto (61) n¼ 80; pro Clinical remission for
3 months
Relapse by the DAI <170 12 months 76 76 — —
Hosseini (493) n¼ 157; pro Clinical remission for
3 months
Seo index > 220; or need
for therapy change
>341 12 months 80 89 — —
Jauregui-Amezaga
(494)
n¼ 70; pro Partial; Mayo  1 Endoscopic Mayo > 0 >100 12 months 64 53 67 88
>250 12 months 78 45 85 88
Ferreiro-Iglesias
(495)
n¼ 20; pro Clinical remission for
6 months with
infliximab
Clinical relapse by the
partial Mayo
>198 2 months 100 81 48 100
Tursi (496) n¼ 20; pro Before starting biologics Active disease by the DAI >15 12 months 66 56 18 92
Endoscopic Mayo¼ 2–3 >15 12 months 47 87 90 37
Theede (497) n¼ 70; pro Clinical remission Relapse requiring therapy
change
>321 6 months 63 86 46 92
>321 12 months 46 86 46 86
Frin (498) n¼ 31; pro 2 weeks after starting
infliximab
Response (by the Mayo
score)
<800 14 weeks 82 69 78 85
14 weeks after starting
infliximab
Sustained remission (by
the partial Mayo score)
without IFX dose
intensification or other
treatments
<146 54 weeks 90 72 86 80
DAI¼Disease Activity Index; FU¼ follow-up; IFX¼ infliximab; NPV¼Negative Predictive Value; PPV¼ Positive Predictive Value; Pro¼ prospective;
Retro ¼ retrospective; UCAI ¼ Ulcerative Colitis Activity Index.
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Exacerbation or disease onset 
Assess disease (Figure 2)1 
Teach coping skills by support programs
INDUCTION OF REMISSION 
Mild disease (PUCAI 10-35)1 Severe disease (PUCAI 65-85)1
Oral 5-ASA at maximal dose2;  
Enemas should be offered and may 
be sufficient in proctitis3 
Oral prednisone 1mg/kg 
once daily up to 40mg + 
5-ASA2, 3 
Taper corticosteroids4 Admission for IV steroids5
Sufficient response 
in 7-14 days 
Sufficient response6
Moderate disease (PUCAI 40-60)1
Systemically ill
Add enemas3 and/or 
probiotics/curcumin; 
May consider oral BDP or, if left 
sided, budesonide-MMX 
Not systemically ill 
Insufficient response 
in 7-14 days
Insufficient 
response
Insufficient 
response in 7-14
Insufficient response
In very selected cases consider infliximab or 
tacrolimus induction treatment instead of admission7 
Sufficient responseInsufficient response
5-ASA for all patients2; Probiotics may be added. Rectal therapy3 may be sufficient in proctitis
If disease is chronically active, or X2-3 annual flares, or severe attack while on 5-ASA, add thiopurines 
(azathioprine 2-2.5 mg/kg once daily or mercaptopurine 1.5mg/kg once daily)8 
If biologic therapy fails (including dose intensification) and other diagnosis ruled-out1 consider colectomy. 
Apheresis may be attempted in very selected children when available 
If disease is still chronically active or frequent flares despite adequate thiopurine treatment, consider infliximab 
(or adalimumab/golimumab in cases of loss of response (Figure 3)) 
MAINTENANCE OF REMISSION 
Stepping down9
Stepping down9
Consider vedolizumab if active disease despite adequate anti-TNF levels or if failed more than one anti-TNF  
FIGURE 3. Summary flowchart of managing pediatric ulcerative colitis (UC). Comments: Medical therapies in UC should be divided into those that
induce remission (5-ASA, corticosteroids, anti-tumurnecrosis factor (TNF) therapy, calcineurin inhibitors and likelyprobiotics) and those that maintain
remission (5-ASA, thiopurines, anti-TNF therapy, vedolizumab and selected probiotics). 1. The following should be considered in active disease:
infectious colitis (including CMV and C. difficile), 5-ASA related colitis, lactose intolerance, irritable bowel syndrome, celiac disease. In case of
discrepancy between PUCAI and endoscopic grading of colitis, endoscopy should prevail. 2. 5-ASA is dosed 60-80 mg/kg/day up to 4.8 grams daily.
Once daily dosing may be as effective as twice daily dosing. 3. 5-ASA enemas (1g daily is as effective as higher doses) are more effective than steroid
enemas. Enemas should be administered in the left decubitus position. Liquid enemas are more difficult to tolerate than foams and suppositories but
are more suitable for extensive colitis. 4. If lack of improvement (i.e. PUCAI decrease of<20 points) after 7–10 days, or increase in PUCAI20 points at
any time, consider treatment escalation. Steroid dependency must be avoided. 5. See Part 2 of these guidelines. 6. Response is defined as a drop in
PUCAI of at least 20 points. However, the goal of induction therapy is eventually complete remission (Figure 2). 7. e.g. previous intolerance or
resistance to steroids, or when infliximab is indicated anyway for maintenance treatment after failing thiopurines. 8. Measuring TPMT (genotyping or
enzymatic activity) at baseline, and 6-TG and 6-MMP levels after 2–3 months, may aid in optimizing thiopurine dosing. 9. If infliximab has been used
in thiopurine-naı¨ve disease, thiopurines may be added and infliximab discontinued after 4–8 months if complete remission has been achieved.
Stepping down to 5-ASA may be considered in selected cases, if 5-ASA did not fail previously, and after a period of sustained deep remission.
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pediatric UC, ESR and CRP should be measured at least initially,
since at times only 1 measure is elevated (49). Initial albumin was the
only significant laboratory test that was predictive for acute severe
colitis in 1 follow-up study (23). Similarly, earlier surgery was
necessary in children with initially low serum albumin (HR 6.05,
99% CI 2.15–17.04) in 57 children who ultimately required colect-
omy (median time to surgery was 3.8 years) (50). In another study,
elevated white blood cell and low hematocrit measured at diagnosis
were associated with colectomy rate at 3 years (51).
Fecal biomarkers reflect especially histological activity (52–
54). High correlation of calprotectin with clinical disease activity,
endoscopic, and histological indices has been described in both
children and adults (52,55–59) (Table 2). In a retrospective pedi-
atric study, calprotectin value of 275mg/g achieved sensitivity and
negative predictive value of 97% and specificity and positive
predictive value of 85% in evaluating histological activity (60).
A few studies have indicated that calprotectin can be useful to
predict relapses in UC patients (56,61,62), but its added predictive
utility while in clinical remission is less clear (Table 3).
Roughly 60% of children with UC are pANCA positive at the
time of diagnosis (63). pANCA positivity was not associated with
disease activity in 1 pediatric study (64), or with early relapse (1-
year follow-up) (65). In a recent Porto group multicenter retrospec-
tive study of 801 children with colonic IBD, pANCA predicted the
need for biologics in UC (P¼ 0.026) (63). In an adult UC popula-
tion, pANCA status was associated with higher risk of pouchitis
after colectomy (66).
Data supporting CRC surveillance recommendations can be
found in extensive adult guidelines (15,16,67). Of note, a Swedish
nationwide cohort study of pediatric IBD confirmed that CRC was
almost non-existent during the first 5 years of follow-up, but
incidence was higher after 10 years of follow-up (68). Interestingly,
the incidence of CRC in the first 20 years of follow-up was
considerably lower in childhood-onset IBD than in disease with
onset at other ages.
MEDICAL MANAGEMENT
5-ASA and Enemas
Recommendations
1. Oral 5-ASA compounds are recommended as
first-line induction and maintenance therapy for
mild-moderate UC [EL2, adults EL1]. (100%
agreement)
2. Combined oral and rectal 5-ASA therapy is more
effective than oral 5-ASA monotherapy [EL2, adults
EL1]. (98% agreement)
3. Rectal monotherapy should be reserved for mild-to-
moderate ulcerative proctitis, an uncommon pedi-
atric phenotype [EL2, adults EL1]. (100% agree-
ment)
4. When rectal therapy is used, 5-ASA is preferred over
steroids [EL5, adults EL1]. (100% agreement)
Practice Points
1. No mesalamine delivery system has proven clearly
superior for induction or maintenance of remission.
Sulfasalazine may be somewhat superior to mesa-
lamine for maintenance of remission in adult
studies. Only sulfasalazine is available in liquid for-
mulation and may be also effective for arthritis, but it
is associated with more adverse events. (100%
agreement)
2. Suggested dosing: oral mesalamine 60 to 80 mg 
kg1 day1 to 4.8 g daily; rectal mesalamine 25 mg/
kg up to 1 g daily; sulfasalazine 40 to 70 mg 
kg1 day1 up to 4 g daily. Higher rectal doses up
to4 g are being used but evidence suggest that it is no
more effective than 1 g. (98% agreement)
3. Suppositories are useful for limited proctitis, while
foam and liquid mesalamine enemas are also suit-
able in more extensive colitis. (95% agreement)
4. Dosing 5-ASA once-daily can be considered for
induction of remission and for maintenance.
(95% agreement)
5. Gradual sulfasalazine dose augmentation over 7 to
14 days may mitigate against dose-dependent side-
effects (see text). (93% agreement)
6. The effective induction dose should be continued
also as the maintenance dose. Dose reduction,
within the suggested dose range, may be consid-
ered after several months of sustained remission.
Maintenance therapy should be continued in pedi-
atric patients. (93% agreement)
7. Most children with mild-moderate UC will not
achieve remission with oral mesalamine monother-
apy alone. Treatment modification should be con-
sidered in those who do not show initial meaningful
response within 2 to 3 weeks of therapy. (95%
agreement)
8. Acute mesalamine intolerance could present as an
exacerbation of the UC, usually within the first
month of treatment. Symptoms resolve within days
of cessation. Recurrence on re-challenge is diagnos-
tic and precludes its future use. Symptoms usually
recur also following rectal administration. (100%
agreement)
9. Rectal tacrolimus may be considered in patients with
ulcerative proctitis who are either refractory or intol-
erant to mesalamine and steroids topical therapies
(suggested dose 0.07 mg  kg1 day1; maximum
dose in adult trials 3 mg/day). (88% agreement)
Strong evidence, mostly from adult trials, supports the use
of 5-ASA for induction and maintenance of remission in mild-
moderate UC (41,69–72). In that context, mesalamine induces
remission in 35% to 55% of children, as defined by the PUCAI
(73,74).
The MUPPIT trial randomized children with mild-moderate
UC into once versus twice daily oral mesalamine (Pentasa), with
comparable outcomes (74). Once daily dosing achieved clinical
response in 25/43 (60%) and remission in 13/43 (30%), compared
with 25/40 (63%) and 16/40 (40%), respectively, for the twice daily
group. Most responders did so by week 2 and no further response
was seen after week 3. While the groups were statistically compa-
rable, more patients in the once-daily study arm had pancolitis and
were already on immunomodulators. Endoscopic remission was
not assessed and the study was not powered for non-inferiority.
Long-term studies of 5-ASA of once daily maintenance in pediat-
rics are currently ongoing. In another pediatric RCT, low versus
higher dose balsalazide induced remission in 3/35 (9%) versus 4/33
(12%) of children, respectively (72). Clinical improvement in
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mild-moderate UC was seen in nearly twice as many children
randomized to sulfasalazine (22/28, 79%) compared to olsalazine
(11/28, 39%) (71).
There are no pediatric maintenance comparative trials of 5-
ASA, but only  40% (86/213) of children treated with 5-ASA
within 1 month of diagnosis were in steroid-free remission by 1 year
in the North American registry (75). Similar data were reported
from the prospective Italian pediatric IBD registry, with 45% of
patients in remission at 1 year on 5-ASA therapy alone (76).
EPIMAD data reported that 32% (36/113) of children with UC
remained on 5-ASA therapy without steroids, by maximum follow-
up (5). In a recent Cochrane analysis of adult trials, the relative risk
of successful induction of clinical and endoscopic remission with 5-
ASA was 1.16 (95% CI 1.12–1.21) and 1.29 (95% CI 1.16–1.69),
respectively (69). No specific 5-ASA compound was superior for
inducing remission, although sulfasalazine was statistically superior
to other 5-ASA compounds for maintenance of remission
(69,70,77,78).
The pharmacokinetics of 5-ASA are comparable between
children and adults (79–81). Adult trials have shown somewhat
greater efficacy of higher induction mesalamine dose in patients
with severe or extensive disease, phenotypes more commonly seen
in children (82–84). In a multicenter RCT, 81 children with mild-
moderate UC were, however, randomized to high dose (53–
118 mg  kg1  day1) or lower dose (27–71 mg  kg1  day1)
delayed release mesalamine with similar PUCAI-defined remis-
sion rates after induction (55% and 56% respectively) (73).
While greater reductions in fecal biomarkers were seen in the
higher dose group, this did not reach significance. This trial
enrolled on average children with milder disease which may
explain the higher remission rates compared to other aforemen-
tioned pediatric trials.
Oral mesalamine may be better tolerated than sulfasalazine
(relative risk of adverse effects 0.48, 95% CI 0.36–0.63), but the
latter is cheaper and remains the only 5-ASA available in liquid
formulation (70,71). Moreover, except for the uncommon allergic
reaction (<0.1%), the vast majority of events are mild (eg, headache
and gastrointestinal symptoms) (85,86). Serious adverse events
with 5-ASA treatment are rare and include renal, pancreatic,
pulmonary, and cardiac complications (87–93). Withdrawal due
to intolerance in adult studies is in the range of 2% to 5% (69,70).
Intolerance to 5-ASA medications may mimic a colitis flare, and
when clinically proven by re-challenge, it precludes further use of
5-ASA compounds (94). Regular laboratory monitoring of full
blood count, renal function, and urinalysis, though not supported
by evidence, remains the practice of many clinicians.
Rectal therapy (as suppositories) is indicated for ulcerative
proctitis, an infrequent phenotype in pediatrics (95). In order to
allay concerns and ensure optimal compliance, children and their
caregivers require support and reassurance when topical rectal
therapies are proposed.
In a pediatric ulcerative proctitis trial, mesalamine suppos-
itories (0.5 g daily) were associated with improved disease
activity at 3 and 6 weeks in children with mild-moderate proctitis
(95). Combining oral and rectal 5-ASA therapy improves clinical
outcomes (96–98). Remission was reported in 16/38 children
(42%) in a prospective uncontrolled trial of 3 weeks’ rectal
mesalamine in patients unresponsive to oral high dose mesala-
mine (99). Adult studies with larger numbers and a higher evi-
dence level have shown that rectal mesalamine foam, gel or
liquid enema formulations have comparable tolerance, safety
and outcomes (100–103). Once daily rectal therapy is as
effective as divided daily dosing (104). In adults, daily doses
in excess of 1 g of rectal mesalamine do not enhance outcomes
including clinical, endoscopic and histological remission
(100,101). Rectal steroid preparations are useful for patients
who are 5-ASA intolerant. They are superior to placebo in
children and adults for inducing remission of proctitis, but
meta-analysis data consistently support the superiority of rectal
mesalamine over rectal steroids (symptomatic remission OR 1.65
[95% CI 1.1–2.45]) (100,101).
Rectal tacrolimus has been reported in children and adults as
a successful third-line treatment of ulcerative proctitis (105,106). In
a recent double-blind placebo-controlled trial, 8/11 adult patients
receiving rectal tacrolimus ointment (1.5 mg twice daily) achieved
mucosal healing by week 8, compared with 1/10 receiving placebo
(107). Although usually well tolerated, rare toxicity episodes have
been reported (106).
TABLE 4. Steroids tapering schedule (doses are in mg/day prednisone equivalent): the goal is to discontinue steroids by week 10
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10
60 50 40 35 30 25 20 15 10 5
50 45 40 35 30 25 20 15 10 5
45 40 40 35 30 25 20 15 10 5
40 40 40 35 30 25 20 15 10 5
35 35 35 30 25 20 15 15 10 5
30 30 30 25 20 15 15 10 10 5
25 25 25 20 20 15 15 10 5 5
20 20 20 15 15 12.5 10 7.5 5 2.5
15 15 15 12.5 10 10 7.5 7.5 5 2.5
Avoid steroid dependency by timely escalation of maintenance therapy when needed. The risk for exacerbation is smaller with prednisone doses>20 mg, but
the risk for adverse events is then higher thus a more rapid tapering to 20 mg is desired. Shortening each stage from 7 to 5 days or any other tapering
modification may be considered individually since many factors come into play when weaning off steroids. Consider the possibility of adrenal insufficiency,
even many months after tapering off steroids.
First 2 to 3 weeks: start prednisone at 1 mg/kg up to 40 mg once daily (after discharge from acute severe colitis admission, the dose may be as high as 60 mg/
day; see part 2 of these guidelines). If there is no significant improvement (ie, PUCAI decrease of<20 points) after 7 to 14 days, or an increase in PUCAI 20
points at any time, then escalate treatment after excluding other causes for steroid-refractory disease (see text and Figs. 2 and 3).
After the first 2 to 3 weeks: PUCAI 15 to 30: consider keeping the dose stable (while prolonging the total course by 1 week); PUCAI> 35, increase steroids to
the dose of the previous 1 to 2 steps for 1 week and then re-start weaning more slowly; PUCAI> 60 or increase in PUCAI by 20 points at any time, escalate
treatment.
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Oral Steroids
Recommendations
1. Oral steroids should be used as second-line treat-
ment for mild-moderate UC not responding to 5-
ASA (oral 	 rectal) and may be considered as first
line in the higher end of the moderate disease range
[EL3, adults EL1]. (100% agreement)
2. Severe UC should normally be treated with intrave-
nous steroids [EL2, adults EL1]. (98% agreement)
3. Second-generation oral steroids with lower systemic
effect such as beclomethasone dipropionate (BDP)
[EL2, adults EL1] and budesonide-MMX [EL5, adults
EL2; the evidence for budesonide-MMX is support-
ive only for left-sided colitis] may be considered in
patients with mild disease refractory to 5-ASA before
oral prednisolone. (93% agreement)
4. Steroids are not recommended for maintaining
remission; steroid sparing strategies should be
applied [EL5, adults EL4]. (100% agreement)
Practice Points
1. Regarding recommendation #2, a short trial of oral
steroids could be considered in selected children
with severe colitis (ie, PUCAI  65) who appear well
with normal or near-normal lab values. (93%
agreement)
2. The recommended daily dose for oral prednisolone/
prednisone is 1 mg  kg1 day1 (max 40 mg) once
daily for 2 to 3 weeks followed by a tapering period
of up to 8 to 10 weeks (Table 4). (98% agree-
ment)
3. Once daily administration of steroids in the morning
is as effective as the same dose given in multiple
divided doses. (100% agreement)
4. In patients >30 kg the dosing schedule of BDP is
5 mg once daily for 4 weeks and for budesonide-
MMX 9 mg for 8 weeks. Dosing for children <30 kg
has not been established and no liquid formulation
is available. There is no evidence to support tapering
of either drug. While abrupt discontinuation has
been practiced in the RCTs, alternate day tapering
over 2 to 4 weeks has been proposed by some.
(93% agreement)
5. The term ‘‘steroid-dependency’’ applies to patients
who are unable to stop steroids within 3 months
without recurrent active disease, or who have a
relapse requiring steroids within 3 months of stop-
ping steroids. (95% agreement)
6. High glucocorticoid dose and long duration of the
therapy (>3 months) has been associated with
adrenal suppression (ie, present after gradual wean-
ing off) in 20% of children with IBD. (98% agree-
ment)
7. If symptoms of adrenal suppression (eg, weakness/
fatigue, malaise, nausea, vomiting, diarrhea, head-
ache, arthralgia, and abdominal pain) are present
while weaning steroids, adrenal insufficiency should
be excluded by first testing cortisol level at 08:00 AM
before drug intake, and, if abnormal, consult with a
pediatric endocrinologist. (93% agreement)
Studies of oral steroids for treating children with active UC
report short-term (1-3 months) remission rates of 50% to 64%
(108–110); at 1 year 49% to 61% had prolonged response, 14% to
49% were steroid-dependent, and 5% to 29% required surgery
(5,7,108,110). Mucosal healing lags behind clinical improvement;
in a non-randomized study after 8 weeks of steroids or 5-ASA, 87%
had clinical remission, 40% endoscopic remission and 15% histo-
logical remission with no significant difference in outcomes
between the 2 therapies (111).
Steroid dependency has been reported to be higher in chil-
dren than in adults (45% vs 8%, respectively) (7). Strategies to
avoid steroid dependency include optimization of 5-ASA, adjuvant
therapy with enemas, and escalation to thiopurines or biologics.
Second-generation topical steroids have a more favorable
safety profile and may be considered before systemic steroids in
selected patients (112). BDP uses gastro-resistant film coatings to
target delivery to the distal small intestine and the colon. Studies in
adults demonstrate the effectiveness of BDP compared with both
prednisolone and mesalamine (15,113). An RCT of 30 children
(weight >30 kg) with mild-to-moderate UC showed that oral BDP,
5 mg/day for 4 weeks, was well tolerated and more effective than 5-
ASA in achieving both clinical remission (80% vs 33%, P< 0.025)
and endoscopic remission (73% vs 27%, P< 0.025), respectively
(41).
A Cochrane systematic review of older selective release
budesonide in adults showed that it was less likely to induce
remission than mesalamine (relative risk [RR] 0.72, 95% confi-
dence interval [CI] 0.57–0.91) with no benefit over placebo (RR
1.41, 95% CI 0.59–3.39) (114). Budesonide-MMX is a novel oral
formulation designed to extend release of the drug to the colon. Two
adult trials showed significant benefit in the intention to treat (ITT)
population (combined left sided and extensive), but subanalysis
based upon disease extent was only significant for left-sided disease
(115,116). Indeed, in a recent case series of 16 children, 15 of whom
with pancolitis, budesonide-MMX showed minimal clinical effec-
tiveness (117). Another recent RCT in adult UC refractory to 5-
ASA showed superiority over placebo but with a disappointing 6%
effect size difference; no subgroup analysis of disease extent was
performed (118).
Children with UC may have more steroid-related complica-
tions, including osteopenia, acne, glaucoma, and cataracts, than
adults even when adjusted for weight (119). Even low steroid doses
(0.1–0.4 mg  kg1  day1) can suppress growth (120). The ECCO
statement in adults suggests supplementation with vitamin D while
on steroid therapy (121), but we could not find clear evidence to
support supplementing vitamin D in those who are not deficient.
AS may present with non-specific symptoms (including
abdominal pain, malaise, weakness/fatigue, nausea, diarrhea, head-
ache, fever, arthralgia) or rarely adrenal crisis (hypotension,
lethargy, decreased consciousness/coma, hyponatraemia, hypogly-
cemia, seizures) (122). There are no published consensus guidelines
that advise who should be screened for AS. In 1 recent review, it was
recommended to screen patients who received steroids for >3
weeks and after gradual weaning have persistent symptoms that
may be attributable to AS (123). The range of 8 AM morning cortisol
value at which AS is confirmed varies between studies. In 1 recent
review a value of <100 nmol/L was used while >500 nmol/L
virtually excluded AS (124). Another manuscript suggested that
<85 nmol/L should be used to diagnose AS (123). In a study of
consecutive children with IBD about to stop steroids (ie, on
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physiological doses of oral steroids meaning 5 to 10 mg daily
prednisolone) 20% had biochemical AS using a value <69 nmol/
L and of these half had an undetectable cortisol (125). Higher
glucocorticoid dose and longer duration of the therapy were asso-
ciated with increased risk (125). In the only study of children with
IBD, all children treated with steroids for <3 months did not have
biochemically confirmed AS (after gradually weaning to physio-
logical doses of steroids) (125–127).
Immunomodulators
Recommendations
1. Thiopurines are recommended for maintaining
remission in children who are corticosteroid-depen-
dent or relapsing frequently (2 relapses per year)
despite optimal 5-ASA treatment and in 5-ASA intol-
erant patients [EL3, adults EL1]; thiopurines should
be considered following discharge from acute
severe colitis episode [EL4, adults EL3]. (98%
agreement)
2. Thiopurines should not be used for induction of
remission in pediatric UC patients [EL5, adults
EL2]. (100% agreement)
3. Measuring thiopurine metabolites is recommended
in patients with incomplete response on a stable
thiopurine dosage, in patients who present with
leucopenia or elevated transaminases, or if poor
compliance is suspected [EL2, adults EL2]. (95%
agreement)
Practice Points
1. Thiopurines may be somewhat more effective than
5-ASA for maintaining remission in UC, but con-
sidering their safety profile, they should generally
be reserved as second-line therapy after 5-ASA has
failed. (93% agreement)
2. Determination of TPMT genotype or phenotype
(ie, TPMT activity) is encouraged to identify
patients at greater risk of profound myelosuppres-
sion. Dose should be reduced in heterozygous
patients or in those with low activity. Thiopurines
should not be used in children homozygous
mutants for TPMT or those with very low TPMT
activity as defined at each laboratory. (93%
agreement)
3. Regular monitoring of blood counts and liver
enzymes is recommended in all cases every 1 to
2 weeks during the first month then every month
up to 3 months followed by every 3 months there-
after. (100% agreement)
4. Families should be instructed to use sun protection
with the use of thiopurines and other immunosup-
pressive drugs. (100% agreement)
5. Given its excellent safety profile, it is reasonable to
continue 5-ASA with thiopurines, at least initially,
despite lack of evidence. 5-ASA inhibits the enzyme
TPMT thus increasing the active metabolite 6-
thioguanine (6-TGN). (88% agreement)
6. The maximal therapeutic effect of thiopurines may
not be evident until 10 to 12 weeks of treatment.
(98% agreement)
7. Thiopurine dose should be approximately 2 to
2.5 mg/kg of azathioprine and 1 to 1.5 mg/kg of
mercaptopurine, in a single daily dose in patients
with a normal TPMT. Measuring thiopurine metab-
olites may assist in further dose adjustments and
reduce adverse events while considering 6-TGN
level of 235 to 450 pmol/8
108 RBCs and 6-
methylmercaptopurine ribonucleotides (6-MMP)
< 6700 pmol/8
108 RBCs as optimal (note that
cutoff values may vary between methods (128)).
(95% agreement)
8. Patients who show gastrointestinal intolerance or
flu-like reaction to 1 thiopurine compound may
tolerate lower doses or a ‘‘switch’’ to another
thiopurine (azathioprine to 6-mercaptopurine
and vice versa). Limited data suggest that splitting
the daily dose into 2, may alleviate gastrointestinal
and hepatic toxicity in patients who have hyper-
active TPMT activity. (95% agreement)
9. Thiopurines should be discontinued in clinically
significant myelosuppression or pancreatitis. Rein-
troduction of thiopurines after leucopenia (but not
usually pancreatitis) can be considered at a lower
dose after carefully assessing the risks and benefits
and after measuring thiopurine metabolites and/or
TPMT. (95% agreement)
10. Change in treatment should be considered in
patients with active disease despite adequate 6-
TGN level after at least 12 weeks of thiopurine
treatment. (98% agreement)
11. Concomitant use of allopurinol) 50 mg once daily
in patients <30 kg and 100 mg once daily is
patients30 kg, maximum 5 mg/kg) with reduced
dose of azathioprine (to approximately 25% to
30% of initial dose), may provide a valid therapeu-
tic option in cases of hyperactive TPMT resulting in
high 6-MMP (often associated with elevated trans-
aminases) and low 6-TGN, in suitably experienced
units. Children must be closely monitored given
the increased risk of toxicity. (95% agreement)
12. Benefits of withdrawal should be carefully weighed
against an increased risk of relapse. Thiopurine
withdrawal could be considered in patients in
sustained clinical remission following long-term
treatment (at least 1 year) after ensuring complete
mucosal healing and preferably also histological
remission. In the case of thiopurine withdrawal, 5-
ASA treatment may assist in maintaining remission
(particularly in patients naı¨ve to 5-ASA). (91%
agreement)
13. Methotrexate may rarely be considered in UC
patients who fail to respond or are intolerant to
thiopurines, when other alternatives are not possi-
ble or available. (91% agreement)
14. Oral tacrolimus (FK-506) may be considered in
selected outpatient UC children as another option
to steroids for bridging to thiopurines or vedolizu-
mab (given the longer time to onset of action).
At initiation, high target serum trough level
(10–15 ng/mL) should be achieved with a
gradual titration to lower trough levels (5–10
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and eventually 2–5 ng/mL) in order to avoid seri-
ous adverse events. Selected patients may benefit
from a long-term, low-dose treatment (ie, drug
level target of 2 ng/mL), but the potential toxicity
should be carefully considered, as well as noting
the limited supportive evidence. (93% agree-
ment)
The efficacy of thiopurines (azathioprine and 6-mercaptopu-
rine) was evaluated systematically for both induction and mainte-
nance of remission in adult UC patients. Meta-analyses of adult data
concluded that azathioprine is not more effective than placebo for
induction of remission but is superior to placebo in preventing
relapse (129–131). In a recent prospective cohort study, sustained
clinical benefit was achieved in 60% of 255 adult UC patients
receiving azathioprine following 5-ASA failure, at a median follow-
up of 30 months (132).
Prospective pediatric studies reported steroid-free remission
rates of 49% at 1 year (133) and 72% at 2 years (134) in thiopurine
treated children with no difference in either clinical or endoscopic
end-points between early or late initiation of treatment. A few
retrospective studies (135–138) in children supported the benefit of
thiopurines in maintaining remission and steroid sparing with a
median time to achieve steady state of thiopurine levels of 55 days
(139). Cox proportional hazard modeling of retrospective data from
1175 incident children and young adults, did not demonstrate a
benefit to early thiopurine use in reducing the risk of colectomy
(140).
Despite 1 negative small adult study (141), it is not unrea-
sonable to combine 5-ASA with thiopurines given the excellent
safety profile of the former and its possible additive effect, includ-
ing chemoprotection. 5-ASA may partially inhibit TMPT activity
and therefore may increase 6-TGN levels (142,143).
Most adult studies used doses of 2.5 mg/kg for azathioprine
and 1.5 mg/kg for 6-MP. There was, however, no clear dose-
response effect for azathioprine, implying that low-dose azathio-
prine (1.5 mg/kg) may not be inferior to standard dose (144).
Children younger than 6 years may require higher doses of azathio-
prine per body weight with doses of up to 3 mg  kg1  day1
(145,146).
The relative risk of serious adverse events with thiopurines
was found to be 2.82 in a Cochrane meta-analysis of adult data
(130). Thiopurine withdrawal rate due to adverse events in large
pediatric cohorts was 18% (147) and 30% (148). Dose-independent
adverse reactions include fever, pancreatitis, rash, arthralgias,
nausea, vomiting, and diarrhea, while dose-dependent toxicities
included leucopenia (up to 5%), thrombocytopenia, infections, and
hepatitis (149,150). A meta-analysis of studies of 6-MP found that it
was tolerated in 68% of 455 adult patients who were azathioprine-
intolerant, lending support to switching between these drugs in
cases of specific dose-independent adverse events (151). Switching
in the case of pancreatitis has traditionally not been recommended
but some recent case series have challenged this notion (151).
A meta-analysis (25,728 IBD patient-years) demonstrated
that patients younger than 30 years have a high relative risk for non-
Hodgkin lymphoma (SIR¼ 6.99) with younger men being at the
highest risk. However, the absolute risk is much higher in the
elderly. In patients younger than 30 years, the absolute risk is
estimated at only 1 in 4000 to 5000 (152). Hepatosplenic T-cell
lymphoma (HSTCL) is a very rare but fatal complication of
thiopurine therapy. Of over 40 reported cases of IBD-related
HSTCL, almost all received thiopurines, with or without anti-
TNF and almost all were males; there are only extremely rare
and anecdotal case reports of children with HSTCL who were
treated solely with anti-TNF (153,154).
TPMT assay (either phenotype or genotype) can be used
before initiation of thiopurines to identify some of the patients who
are at risk for dose-dependent myelosuppression, and in whom this
drug should either not be used (if homozygous for variant alleles or
have very low TPMT activity) or administered at lower dosage (if
heterozygous for variant alleles or having low TPMT activity).
TPMT testing does not, however, replace the need for mandatory
monitoring of complete blood cell count especially during initiation
of treatment. In an adult study (155), a significantly smaller
proportion of carriers of a TPMT variant with adjusted dose
developed hematologic adverse events (RR¼ 0.11). In a pediatric
study, 7 of 46 (15%) carriers of at least 1 variant allele or low/
intermediate TPMT activity developed myelosuppression com-
pared to 0/62 in the wild type/high activity group (156). In contrast,
a study of 72 children showed no association between TPMT
polymorphisms and the occurrence of thiopurine-related adverse
events (157).
In the case of hyperactive TPMT resulting in high 6-MMP
and low 6-TGN, concomitant use of allopurinol with reduced dose
of azathioprine may provide a valid therapeutic option (158,159)
but needs to be used with caution. Adequate dose reduction and
repeated monitoring of CBC and 6-TGN/6-MMP is essential to
avoid myelosuppression related side effects. In adult trials, allopu-
rinol was used at 100 mg once daily (158,160) whereas in the few
pediatric case series lower doses (50 or 75 mg once daily) were
utlized in younger children (159,161).
Therapeutic drug monitoring, namely measurement of thio-
purine metabolites, specifically 6-TGN and 6-MMP levels, has been
implemented as a means of optimizing efficacy and avoiding
myelosuppression. In a meta-analysis which included 1026 IBD
children (162), higher 6-TGN concentrations were not consistently
associated with leucopenia, while marginally associated with
greater likelihood of clinical remission. High 6-MMP levels corre-
lated with hepatotoxicity, and low thiopurine metabolite levels with
non-compliance. In a retrospective study including 86 IBD children,
6-TGN levels of >250 pmol per 8
 108 red blood cells correlated
with a higher response rate (OR¼ 4.14) (163). The association
between both bone marrow toxicity and clinical response with 6-
TGN levels was demonstrated in prospective adult studies
Adequate levels 
≥4-5μg/ml in IFX and ≥5-8μg/ml in ADA1
Increase dose, decrease 
frequency and/or add IMM
Acve disease while treated with inﬂiximab (IFX) or adalimumab (ADA)
1. Ensure compliance
2. Exclude infecons, medicaons side 
eﬀects, IBS and other diagnoses 
Negave or low Ab tre
≤9μg/m in IFX 
≤4μg/m in ADA
Switch to a drug out of an-
TNF class (e.g. vedolizumab)
Low levels 
<4-5μg/ml in IFX and <5-8μg/ml in ADA1
High Ab tre
>9μg/m for IFX 
>4μg/m for ADA
Switch to another an-TNF 
medicaon 
FIGURE 4. Practical interpretation of drug levels and antibodies for
infliximab and adalimumab. Different countries use different measur-
ing kits with different cutoff values; absolute drug and antibodies
levels should be adapted accordingly. (1) Some studies (and the AGA
recommendation in adults (210)) suggest that higher levels for inflix-
imab (>5mg/mL) and adalimumab (>8mg/mL) should be the goal
(see text).
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(164,165) as well as several retrospective pediatric cohort studies
(163,166,167). Dose adjustment following measurement of metab-
olites was reported to increase disease remission rate (168). Chil-
dren with IBD were shown to experience fewer exacerbations when
thiopurine metabolites were measured (169). In a study of 78 IBD
children, 6-TGN level above 405 pmol/8
 108 RBCs was the only
predictor for azathioprine resistance (OR 10.8) implying that
patients with active disease and adequate 6-TGN level should
receive alternative therapies (170).
Thiopurine withdrawal after attaining sustained remission is
controversial. In a retrospective study of 127 UC patients in
remission, approximately one-third relapsed within 12 months
following withdrawal, and two-thirds within 5 years (171). Moder-
ate/severe relapse rate of 26% at 2 years was observed in 108 UC
patients who withdrew treatment following prolonged thiopurine
treatment (172).
Cochrane meta-analyses of methotrexate (MTX) for induc-
tion (2 RCTs, 101 patients) (173) or maintenance (3 RCTs, 165
patients) (174) of remission in adult UC concluded that there is no
evidence supporting the use of MTX for either induction or
maintenance of remission in UC. Nevertheless, this conclusion
relies on low-quality evidence. In the METEOR double-blind,
placebo-controlled trial of 111 steroid-dependent UC adults, ste-
roid-free remission at week 16 was not statistically different than
placebo (32% vs 20%, respectively; P > 0.05) though clinical
remission did differ (42% vs 24%, respectively; P¼ 0.04) (175). In
a retrospective study of 32 UC children unresponsive or intolerant
to thiopurines, response/remission was achieved in 72%, 63% and
50% of patients treated with parenteral MTX at 3, 6, and 12 months,
respectively (176).
Tacrolimus has been studied in ambulatory UC patients (177).
An RCT comparing high target trough level of tacrolimus (10–15 ng/
mL) versus low trough level (5–10 ng/mL) versus placebo in adult
moderate-to-severe UC patients who were hospitalized for the study,
reported a significantly higher response rate in the high trough group
(68% vs 38% vs 10%, respectively) (178). A retrospective cohort
study of 25 ambulatory moderate-to-severe adult UC patients
reported 52% clinical improvement and 44% clinical remission at
6 months (179). Three small retrospective pediatric studies, includ-
ing 18 steroid refractory/dependent UC patients (180), 10 (181), and
8 (182) steroid-resistant patients treated with tacrolimus, reported
50% to 95% response rate; however, colectomy was eventually
performed in most patients during the follow-up period. In a sub-
group analysis, steroid-dependent patients had a significantly higher
long-term colectomy free rate when compared with steroid refractory
patients (78% vs 0%) (180).
Biologics
Recommendations
1. Infliximab (IFX) should be considered in chronically
active or steroid-dependent UC, uncontrolled by 5-
ASA and thiopurines, for both induction and main-
tenance of remission [EL2, adults EL1]. (100%
agreement)
2. Adalimumab [EL4, adults EL4] or golimumab [EL4,
adults EL3] could be considered in those who ini-
tially respond but then lose response or are intoler-
ant to IFX, based on serum levels and antibodies
(Fig. 4). (95% agreement)
3. Adalimumab and golimumab have no role in
patients with primary non-response to IFX [EL4,
adults EL4]. (93% agreement)
4. Vedolizumab should be considered in chronically
active or steroid-dependent patients as second-line
biologic therapy after anti-TNF failure [EL4, adults
EL2]. (95% agreement)
Practice Points
1. Screening for latent tuberculosis with combination
of patient history, chest x-ray, tuberculin skin test, or
interferon-gamma release assays (quantiferon) is
essential before initiating anti-TNF. The quantiferon
test is preferred in patients under immunosuppres-
sive therapy and in BCG immunized patients.
Screening for hepatitis B and C viruses, varicella
zoster virus, and HIV when appropriate, is also
recommended if not done recently. (95% agree-
ment)
2. In ambulatory patients with UC, IFX should be
administered initially at 5 mg/kg per dose (at weeks
0, 2, and 6 followed by 5 mg/kg every 8 weeks for
maintenance). Higher initial dosing should be con-
sidered in children with low body weight (<30 kg)
or high BMI, and in the presence of higher inflam-
matory burden and hypoalbuminemia. Target
trough levels post induction (week 14) and subse-
quent doses are reported in different studies as >4
to 5mg/mL. Rapid infusion (over 1 hour) seems as
safe and effective as traditional slower infusions, if
the induction doses were well tolerated and dose is
stable. (98% agreement)
3. IFX is recommended to be used preferably in com-
bination with an immunomodulator (IMM) (with
the most evidence in UC being thiopurines) in order
to reduce the likelihood of developing antibodies to
IFX (ATI) and in thiopurine-naı¨ve patients to
enhance effectiveness. Discontinuation of the
IMM may be considered after 6 months, especially
in boys, preferably after ensuring trough IFX level
>5mg/mL, since levels may decrease after stopping
IMM. (98% agreement)
4. The utility of combination adalimumab, golimu-
mab, and vedolizumab with thiopurines is more
controversial and they are most commonly pre-
scribed as monotherapy in children. (100%agree-
ment)
5. Golimumab recommended doses for induction are
200 mg at week 0 followed by 100 mg at week 2 for
those weighing 45 kg. Children with lower weight
should be dosed based on body surface area (115
and 60 mg/m2 at weeks 0 and 2). Maintenance
doses q4w are 60 mg/m2 if weight <45 kg and
100 mg if weight 45 kg. Target trough levels dur-
ing maintenance are >2mg/mL. (100% agree-
ment)
6. Extrapolating from pediatric Crohn disease, adali-
mumab should be started at 160 mg, followed by
80 mg after 2 weeks and then 40 mg every other
week in adolescents with weight >40 kg. Optimal
dosing in younger children has not been well
defined, but BSA-based dosing could be considered
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taking as a base an adult BSA of 1.73m2 (ie, induc-
tion with 92 mg/m2 followed by 46 mg/m2 followed
by 23 mg/m2 every other week for maintenance).
Adalimumab target levels during maintenance are
reported in different studies as >5 to 8mg/mL.
(100% agreement)
7. Measurement of drug levels and anti-drug antibody
levels following induction (ie, at the week 14 infu-
sion for IFX and at 8–10 week for adalimumab) can
assist in optimizing treatment. Measuring drug
levels is also useful in the assessment of unsatisfac-
tory response to anti-TNF to guide dose escalation
or a switch to another biologic (see text). (98%
agreement)
8. Standard vedolizumab dosing in adults has been
adapted in pediatric studies (5 mg/kg up to 300 mg
per dose at weeks 0, 2, 6 followed by every 8 weeks
thereafter). For those weighing <30 kg, higher dose
per kg is required, but BSA-based calculation may be
preferred (ie, 177 mg/m2). The effect of vedolizu-
mab in UC has been described to occur by week 6 of
treatment, but complete response may not be
apparent until week 14. Shortening of interval
between infusions to 4 weekly may be required
during maintenance in partial responders. (93%
agreement)
9. In patients with persistent symptomatic distal
inflammation despite adequate optimal anti-TNF
treatment, addition of rectal therapies (preferably
5-ASA) could be beneficial. (98% agreement)
A Cochrane systematic review of 7 adult UC trials concluded
that IFX is effective in inducing clinical remission, promoting
mucosal healing, and reducing the need for colectomy in patients
with active UC (183). Combination therapy with IFX and azathio-
prine was shown to be superior in the SUCCESS trial in adult UC to
monotherapy with azathioprine or IFX alone, while there was no
superiority of IFX monotherapy over azathioprine (184).
In the pediatric UC regulatory RCT (ie, the T-72 study), 45 of
60 (75%) ambulatory children with moderate-severe UC responded
to a standard induction protocol of IFX (40). Both clinical remission
(PUCAI < 10 points) and complete mucosal healing (Mayo endo-
scopic subscore ¼ 0) were achieved in 33% at week 8. Dose
escalation to 10 mg/kg was required in 44% of the patients in
the maintenance phase.
Different studies in children have shown a pooled long-term
success rate of IFX in UC of 64% (185), and a corticosteroid-free
remission of 38% and 21% at 12 and 24 months, respectively, with a
likelihood of avoiding colectomy at 2 years of 61% (186). A
relationship between the increased use of anti-TNF agents and
the reduction of surgery risk for UC children has also been
suggested (187).
Adalimumab has shown efficacy and safety for induction and
maintenance in the adult moderate-to-severe active UC. In the adult
ULTRA-1 trial, clinical remission was obtained in 18.5% of
patients in the 160/80 mg group, 10% in the 80/40 mg group and
9.2% in the placebo group (188). In the ULTRA-2 trial, overall rates
of clinical remission for active drug at week 52 were 17.3%, with
better results among anti-TNF-naı¨ve patients (22%) as compared to
those anti-TNF experienced (10.2%) (189). A network meta-analy-
sis of 5 RCTs in moderate-to-severe adult UC suggested that while
IFX is more effective than adalimumab in the induction of remis-
sion, response and mucosal healing, both are comparable in efficacy
at 52 weeks of maintenance treatment (190). Another meta-analysis
showed superiority of IFX over adalimumab in inducing and
maintaining endoscopic healing in UC (191). In a propensity score
adjusted analysis, a study of 419 adults with UC found no difference
in the effectiveness of these agents, but the adalimumab group was
relatively small (192).
In a retrospective cohort study of 188 children, Vahabnez-
had et al showed that 60% of UC children who discontinued
IFX were commenced on adalimumab, with 83% of these remain-
ing on adalimumab at last follow-up (193). In another retros-
pective study, 55% of UC children switched to adalimumab
after IFX failure, achieved and maintained clinical remission at
a median of 25 months while 36% underwent colectomy (194).
There are no published data on adalimumab in UC children naı¨ve to
anti-TNF.
A second subcutaneously administered, fully human anti-
TNF agent, golimumab, has been studied in placebo-controlled
trials among anti-TNF-naı¨ve adults with moderately-severely active
UC in the PURSUIT-SC (195) for induction, and PURSUIT-M
(196) for maintenance. Golimumab use in pediatric UC was studied
in an open-label pharmacokinetic study of 35 children with moder-
ate-severe UC (197,42). Doses given subcutaneously at weeks 0 and
2 were 90 and 45 mg/m2 for children weighing <45 kg and 200 mg
followed by 100 mg for those weighing 45 kg. Maintenance doses
of 45 mg/m2 if weight <45 kg and 100 mg if weight 45 kg were
given every 4 weeks. Among week 6 Mayo clinical responders
(60%) who continued to receive 4 weekly golimumab maintenance,
57% were in PUCAI remission at week 14. Complete mucosal
healing at week 6 was achieved in 23%, slightly higher than
reported in the adult trials. While the pharmacokinetics data of
the entire pediatric cohort were comparable with those previously
reported in the golimumab adult trials, drug levels in the subgroup
of children weighing <45 kg were numerically lower than those
45 kg. This likely stems from the under-dosing of the former
group. The equivalent dosing of 200 mg in adults and adolescents
would translate to 115 mg/m2 in BSA (considering 200 mg/1.73 m2)
followed by 60 mg/m2 for maintenance. Given the lower drug levels
in the pediatric study, these higher doses should be considered
in practice.
In general, response to anti-TNF medication can occur as
early as 1 to 4 weeks and peaks by week 12 to 16 of treatment
(188,189,198). During induction, trough level of 15mg/mL at
week 6 best predicted likelihood of short-term mucosal healing
(area under the ROC of 0.69) (199). Recommended optimal levels
for IFX during maintenance therapy for improved clinical outcomes
has been defined as >4mg/mL (200–202), for adalimumab >5mg/
mL (203,204), and for golimumab >1.4mg/mL (205). For mucosal
healing, adult studies from both UC (206,207) and CD (207,208),
however, suggested that higher adalimumab level 7.1 to 9.4mg/
mL may be more appropriate. Similarly, IFX trough levels >5mg/
mL were associated with mucosal healing in adult IBD (207) and
with a decreased risk for loss of response when withdrawing
concomitant immunomodulators (209). The American Gastroenter-
ological Association guidelines thus recommend using higher
cutoff values of 5 mg/mL for IFX and 7.5 mg/mL for adalimu-
mab (210).
Drug and antibody levels should dictate the course of action
in patients with secondary loss of response (211) (Fig. 4). Ongoing
symptoms despite adequate drug levels, mandates switching ther-
apy ‘‘out of class.’’ High antibodies titer predicts failure of dose
intensification (211) (Fig. 4).
Factors predicting lower drug levels (and thus possibly
dictating higher dosing) include higher body mass index (212),
low body weight <30 kg (213–215), male gender (216), high
inflammatory burden (extent and severity of disease) (217),
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hypoalbuminemia (218), the presence of anti-drug antibodies, and
the absence of a concomitant immunomodulator (184,219–221).
Safety issues of anti-TNF include acute infusion reactions
(within 4 hours of infusion), delayed hypersensitivity reactions
(beyond 4 hours in both lines of infusion and up to 14 days), serious
and opportunistic infections (222), and a potential risk of skin
cancer; evidence to date does not indicate that anti-TNF is associ-
ated with lymphoma if prescribed as mono-therapy, but a recent
study challenges this concept (223). Psoriasis has been well docu-
mented as an adverse class effect of anti-TNF, but it is usually mild
and controllable in the majority of patients with topical therapy
(224). Other very rare adverse events, such as demyelination events
and optic neuritis, have been reported (225).
There is no clear evidence that pre-medication with any drug
prevents the development of acute infusion reaction (226,227). A
self-reporting system in the United States with >5000 documented
patients calculated a rate of infusion reactions of 3% (1.1% imme-
diate and 1.7% delayed) in IBD-treated patients (228).
Required infectious screening before initiation of anti-TNF
treatment includes testing for HBV, HCV, HIV, VZV, and tubercu-
losis according to local prevalence and national recommendations
(229). The risk of reactivation of other viruses (eg, CMV, EBV) is not
clear. A recent systematic review and meta-analysis including 49
RCT comprising>14,000 patients treated with biologics (anti-TNF,
natalizumab, and vedolizumab) concluded that their use has a
moderate risk of any infection (OR 1.19 (95% CI 1.1–1.29)) and
a significant risk of opportunistic infections in IBD (OR 1.90 (1.21–
3.01)) (230). In another study, the estimated risk of severe infections
in IBD patients treated with anti-TNF has been reported as 2.2%
(231). Concomitant immunosuppressant treatment, particularly ster-
oids, is an additional risk for opportunistic and other infections.
Surprisingly, the meta-analysis found a reduced risk of serious
infections (OR 0.56 (0.35–0.9)) and no increased risk of malignan-
cies (OR 0.9 (0.54–1.5)), but for the latter outcome the data were
insufficient in terms of exposure and follow-up period (230). Studies
report conflicting results regarding the risk of anti-TNF and the risk
for melanoma and non-melanoma skin cancer (232,233).
DEVELOP is a prospective post-marketing industry-initiated
safety registry for pediatric IBD, which includes both patients
exposed and never exposed to IFX (234). In 5766 patients (29%
UC; 24,543 patient years follow-up; median 4.5 years per patient
follow-up) there were 15 malignancy events (13 exposed to thio-
purines (10 with IFX; 3 thiopurine only); 1 only to IFX; 1 to neither
biologics nor thiopurines). Comparison with rates from the SEER
database of healthy controls indicated a standardized incidence rate
(SIR) for neoplasia of 2.43 (95% CI 1.29–4.15) for thiopurine
exposure (with or without biologic exposure), but no significant
increase in neoplasia with IFX exposure in the absence of thiopurine
exposure (SIR 1.49, 95% CI 0.04–8.28). Five children in total
experienced hemophagocytic lymphocytic histiocytosis (HLH), 4
with primary EBV infection, one with CMV infection, and all
during thiopurine monotherapy.
Vedolizumab is a humanized anti-a4b7 integrin that down-
regulates intestinal inflammation by specifically inhibiting intesti-
nal T-lymphocyte migration into the tissue. In the adult GEMINI-1
study in UC, 47% of patients responded to 2-dose induction (300 mg
per dose) by week 6 and were re-randomized to continued vedo-
lizumab 300 mg intravenously (4 weekly vs 8 weekly vs placebo).
The 52-week remission rates among initial week 6 responders
were 42% (q8w) and 45% (q4w) (235), regardless of the prior
anti-TNF exposure status (236,237). This is supported by pharma-
cokinetic data demonstrating significant correlation between higher
vedolizumab drug levels and clinical response in IBD patients
(238–240).
Experience with vedolizumab in pediatric UC is currently
limited to small retrospective cohorts, almost all with prior anti-
TNF failure. The 14-week remission rates were 37% (n¼ 41
definition of remission included steroid-free and utilized ITT rates)
(241), 40% (n¼ 5; (242)), and 76% (n¼ 22 (243)). The 22-week
corresponding remission rates in the 3 studies were 34%, 40%, and
71%, respectively. There is no evidence that combination therapy
with IMM is superior over sole vedolizumab treatment based on
very limited data from adults (244) and children (241).
Limited safety data are reported for vedolizumab in children.
Conrad et al reported 29 adverse events in children including upper
respiratory tract infections, nausea, fatigue, headaches, nasophar-
yngitis, skin infections, and sinusitis (242). Pruritus, infusion
reaction, and nasopharyngitis (1 each) was also reported by the
Paediatric IBD Porto group of ESPGHAN (241).
In a recent network meta-analysis in adults, IFX, adalimu-
mab, golimumab and vedolizumab were all superior to placebo for
maintenance of remission and response; however, superiority of 1
agent over another could not be clearly established (245).
Other Interventions
Recommendations
1. Granulocyte/monocyte apheresis should not be
routinely used in pediatric UC [EL4, adult EL2].
(100% agreement)
2. Fecal microbiota transplantation (FMT) should not
be routinely used in pediatric UC [EL4, adult EL1].
(100% agreement)
3. Antibiotics should not be routinely used for induc-
tion or maintenance of remission of pediatric UC
[EL5, adult EL2]. (100% agreement)
4. Probiotic agents (eg, VSL#3 [Table 5], Escherichia
coli Nissle 917) may be considered in mild UC as an
adjuvant therapy or in those intolerant to 5-ASA
[EL2, adult EL2]. (100% agreement)
5. Curcumin may be considered as an add-on therapy
for inducing and maintaining clinical remission of
mild-to-moderate UC [EL4, adult EL1]. (91%
agreement)
6. Germinated barley foodstuff, omega-3, aloe vera,
herbal medicine, and intravenous immunoglobulin,
are not recommended as primary treatment [EL5,
adult EL2]. (98% agreement)
Practice Points
1. If apheresis is considered, then the most commonly
utilized scheme involves 1 session per week of gran-
ulocyte/monocyte apheresis for 5 to 10 consecutive
weeks. (93% agreement)
TABLE 5. Paediatric VSL#3 dosing (by Miele et al (279))
Age, y Weight, kg Daily/dose, bacteria/day
4–6 17–23 1 sachet (450 billion)
7–9 24–33 2 sachets (900 billion)
11–14 34–53 3 sachets (1350 billion)
15–17 54–66 4 sachets (1800 billion)
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2. VSL#3 dosing may be seen in Table 5. E coli Nissle
1917 strain is prescribed as 200 mg/day in adults
and adolescents. No dosing recommendation is
available for young children. (98% agreement)
3. Neither the formulation nor dosage of curcumin
(the active ingredient of tumeric/curcum) are estab-
lished for children but evidence suggests that it can
be safely used up to 4 g/day for induction and up to
2 g/day during maintenance. The induction dosing
of an ongoing pediatric trial is as follows: (all doses
are daily, prescribed as 2 divided doses): 4 g for
children over 30 kg, 3 g for 20 to 30 kg and 2 g
for those under 20 kg (safety has not been estab-
lished in infants). Doses may be halved for mainte-
nance treatment. (98% agreement)
Apheresis acts by an extracorporeal removal of leukocytes
and other cells of the immune system (granulocytes, granulocyte/
monocyte) through an adsorptive system of cellulose acetate beads
(Adacolumn, Otsuka Pharmaceuticals, UK), or a polyester fiber
filter (Cellsorba, Asahi Medical Company). Overall, pediatric data
suggest a possible clinical efficacy of apheresis in children with
both steroid-dependent and resistant UC, with reported response
rates ranging between 60% and 85%, although they are mainly
small case series or cohort studies (246–251). Data in adults are
conflicting, with some observational and randomized clinical trials
suggesting benefit (252–257), others, among them a large random-
ized, double-blind clinical trial evaluating active versus sham
apheresis, showing no efficacy (258). A systematic review pub-
lished in 2010 reported that, although there may be some efficacy in
specific settings, concerns about methodological quality of identi-
fied studies prevent a rigorous meta-analysis and definitive con-
clusions (259).
FMT is based on the transfer of stool from a healthy donor,
with a presumed healthy diverse microbiome, to a patient. Related
or unrelated donors can be used, and they must undergo an accurate
clinical and laboratory screening before the procedure. Some
studies have used specifically prepared fresh stools, although frozen
stools seem to have the same efficacy and safety (260), with
delivery both to the upper gastrointestinal tract through nasogastric
tube or to the lower gastrointestinal tract through colonoscopy or
serial enemas. A few case series on the efficacy of FMT in pediatric
UC have been published, reporting inconclusive results (261–263).
The largest pediatric series (9 children with UC) showed a 33%
clinical remission (PUCAI < 10) with serial enemas (261). One
small pediatric study reported no clinical improvement after FMT
delivered via nasogastric tube (262). Overall, the safety profile
appears acceptable, although mild-to-moderate side effects were
common, and a case of transitory systemic reaction (profuse
sweating, vomiting, paleness, tachycardia, and fever) has been
reported (264). There may be a theoretical risk pertaining the
transfer of an adult microbiome to a child, particularly very young
with a developing microbiome, to quickening of immune aging and
developing immune-related consequences (265). Rapid weight gain
and the development of autoimmune disease have been reported
after FMT in adults and in animal models (266–268).
Two small RCTs in adults with active UC reported different
results: one showed clinical and endoscopic benefit of FMT admin-
istered via enema compared to sham (269); the other reported no
difference between FMT using healthy donors or autologous feces
administered via naso-duodenal tube, although the limited number
of patients and the route of administration may have impacted on
these results (270). Interestingly, patients who responded to FMT
from a healthy donor restored their altered microbiota toward the
healthy donor composition, while non-responders had no changes.
Recently, the results of a third large, randomized, placebo-con-
trolled trial in active UC resistant to conventional treatment have
been reported (271). Eighty-one adults with UC were randomized to
receive a single FMT or placebo colonoscopic infusion on day 1,
followed by FMT or placebo enemas 5 days per week for 8 weeks.
Each active enema was derived from 3 to 7 unrelated donors.
Steroid-free clinical remission with endoscopic response was
achieved in 11/41 (27%) patients receiving FMT compared to 3/
40 (8%) patients receiving placebo (P¼ 0.02). Microbial diversity
increased and persisted after FMT while Fusobacterium spp was
associated with lack of remission. Although FMT is gaining
increased enthusiasm, the ideal donor and method of administration
should be first determined before this can be incorporated outside
the research setting.
Probiotics have been evaluated for induction and mainte-
nance of remission in UC. One pediatric and 3 adult trials found E
coli Nissle 1917 to be as successful as mesalamine in maintaining
remission (272–275). The dosage used in all these studies, includ-
ing the pediatric one, is 200 mg/day (100 mg contains 25
 109
viable E coli bacteria), administered as capsules. A recent system-
atic review and meta-analysis suggests that E coli Nissle is equiva-
lent to mesalamine to prevent relapse, while its efficacy is
comparable to placebo in the induction of remission (276). A
previous Cochrane systematic review, however, highlighted several
methodological limitations in the maintenance studies, preventing
any conclusion (277).
A small randomized, placebo-controlled trial of 29 children
treated with 5-ASA reported that the combination of VSL#3 in
conjunction with concomitant steroid induction and mesalamine
maintenance treatment was superior to placebo in inducing and
maintaining 1-year remission (278). A small open-label study in 18
children with mild-moderate UC evaluated the efficacy of VSL#3
added to standard treatment with 56% remission rate (279). Overall,
adult data suggest a therapeutic benefit of VSL#3 in the mainte-
nance of remission, supported by a systematic review (280). Studies
on VSL#3 in IBD patients were performed on the original formu-
lation containing 8 bacterial strains (Lactobacillus paracasei DSM
24733, Lactobacillus plantarum DSM 24730, Lactobacillus aci-
dophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgar-
icus DSM 24734, Bifidobacterium longum DSM 24736,
Bifidobacterium infantis DSM 24737, Bifidobacterium breve
DSM 24732, and Streptococcus thermophilus DSM 24731). Chang-
ing the manufacturing processes by different manufacturers may not
have the same clinical efficacy and safety. Scarce published data
report varying content of live/dead bacteria in various VSL#3
products and differences in effect on intestinal epithelial cell status
(281,282). More studies are, however, needed to confirm these data
and no changes in the recommendations are warranted at this stage.
One randomized pediatric trial showed that rectal enemas of
Lactobacillus reuteri ATCC 55730, added to oral mesalamine,
were superior to placebo for inducing remission in left-sided UC
(283).
Antibiotics have been evaluated as a therapy for UC both in
the induction of remission and to prevent disease relapses as shown
in 2 systematic reviews and meta-analyses (284,285). Both included
9 RCTs and concluded that antibiotics may improve outcomes in
UC, but further studies are required to confirm this benefit since the
included trials were very heterogeneous in their methodology and
the type of drug intervention. The use of antibiotics in treating
pediatric UC outside the research setting awaits further trials.
Recently, a small case series on the tolerability of curcumin
added to standard therapy in pediatric IBD has been published,
reporting an acceptable tolerability and a possible signal of benefit
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(286). Two placebo-controlled trials conducted in adults suggested
the possible efficacy of curcumin in achieving and maintaining
sustained clinical remission (287,288). Moreover, endoscopic
remission was observed in 38% (8/22) patients treated with curcu-
min, compared with 0% (0/16) in the placebo group (288). A recent
randomized, placebo-controlled, pilot study reported efficacy of
topical curcumin as enema, added to oral mesalamine, compared to
placebo, in 45 adults with mild-moderate proctitis/proctosigmoidi-
tis (289).
Systematic review of complementary and alternative medicine
treatments in IBD, including aloe-vera, andrographis paniculata,
artemisia absinthium, barley foodstuff, boswellia serrata, cannabis,
evening primrose oil, Myrrhinil intest, plantago ovata, silymarin,
sophora, tormentil, wheatgrass-juice, and wormwood reported a
possible benefit of some interventions, although, given the small
number of trials and their heterogeneous methodological quality, no
definite conclusions could be drawn (290,291). Of note, oral aloe vera
has been evaluated in a double-blind, randomized, placebo-controlled
trial as an adjuvant therapy in 44 adults with mild-to-moderate UC
(292). Higher remission and response rates with improvement of the
histological score were reported in the aloe vera group. These
encouraging but preliminary findings await confirmation before aloe
vera can be recommended for clinical practice.
Other complementary therapies, including germinated barley
foodstuff and herbal medicine have been studied in adult case series
or prospective cohorts. Because of sample size, study design,
concomitant therapies and methodological limitations, these agents
cannot currently be recommended for treating pediatric UC
(290,291,293).
A systematic review and a meta-analysis reported no efficacy
of omega-3 supplement for maintaining remission in UC (293–
295). Recently, a retrospective individual cohort study of 24 adults
with IBD suggested efficacy and safety of intravenous immuno-
globulin in the short-term management, when standard therapies are
contraindicated (296). There are, however, no RCTs on its role both
in adults and children.
Inflammatory Bowel Disease-unclassified
Recommendation
1. Treatment of IBDU patients should broadly follow
that of UC patients of a similar disease severity [EL4,
adult EL5]. (98% agreement)
Practice Points
1. A diagnosis of IBDU should only be made after a
complete assessment including ileocolonoscopy,
gastroscopy, and small bowel imaging. (100%
agreement)
2. A lower threshold for disease reassessment should
be adopted in patients with IBDU before treatment
change. (95% agreement)
3. Although not validated for this indication, it is rea-
sonable to use the PUCAI score to assess disease
activity also in IBDU given the similarity of IBDU,
clinically, to UC. (98% agreement)
4. A multi-item algorithm should be used to standard-
ize the diagnosis of IBDU (Fig. 1; Table 1). (98%
agreement)
5. While ASCAþ/ANCA profile is more suggestive of
CD, and ASCA/ANCAþ of UC, their diagnostic
accuracy is too low to be used in isolation in the
setup of IBDU. (98% agreement)
Patients with IBDU represent approximately 5% to 10% of
pediatric IBD without a decline in incidence over time despite
improved diagnostic measures. The rate is even higher in very early
onset IBD. Complete examination is important, however, and the
proportion of patients with IBDU is reduced if a full diagnostic
work up is performed (297). IBDU is not a misclassification but
rather a true overlap diagnosis within the spectrum of phenotypes
between UC and Crohn colitis (12). Historically, patients with
IBDU have often been poorly classified with no specific guidance
available for detailed diagnostic criteria. The PIBD-Classes criteria
were validated on a large multicenter dataset of 749 patients with
colonic IBD from the Paediatric IBD Porto group of ESPGHAN
(12). A diagnostic algorithm combining 23 features of different
weightings (grouped in class 1, 2, and 3 features) (Table 1) may
differentiate between patients with UC, atypical UC, IBDU, Crohn
colitis and ileal/ileocolonic Crohn disease (Fig. 1) (12).
Given the rarity of IBDU and the hitherto lack of standard-
ized diagnosis, there are very few studies which have been able to
collect treatment information on significant numbers of patients.
The aforementioned retrospective study from the Porto group of
ESPGHAN utilized the data of 537 children with colonic IBD,
including 260 IBDU, to explore common treatment schemes and to
compare the treatment outcomes (298). This study demonstrated
that treatment for IBDU and UC were broadly similar with the most
common treatment used initially being 5-ASA. The use of steroids
was lower than in UC; thiopurines and IFX use was broadly similar
to patients with UC and lower than for patients with Crohn disease.
Rates of surgery were lower than in Crohn disease and UC and the
disease was more likely to be mild at follow-up compared to the
other IBD subtypes, despite the similar use of medications as in UC.
This suggests that treatment can follow that of UC initially with a 5-
ASA regimen.
SURGICAL CONSIDERATIONS (RELATED TO
BOTH PART 1 AND 2 OF THESE GUIDELINES)
The Surgeon’s Perspective
Recommendations
1. Elective colectomy should be considered in children
with active, or steroid-dependent, UC despite opti-
mized medical therapy, and in those with colonic
dysplasia [EL4, adult EL3]. (98% agreement)
2. Restorative proctocolectomy with ileal pouch-anal
anastomosis (IPAA; J pouch) and a covering loop-
ileostomy is the recommended elective surgery for
pediatric UC [EL3, adult EL3]. (93% agreement)
3. Three-stage procedure (subtotal colectomy with
ileostomy first) is recommended for patients with
acute severe colitis, treated with high-dose steroids,
or recent anti-TNF therapy, severe malnutrition, or
IBDU; however, the final choice of the surgical
approach should be individualized [EL4, adult
EL3]. (98% agreement)
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4. A minimally invasive laparoscopic approach is
recommended in children as there are equivalent
outcomes to open surgery both for urgent and
elective cases and possibly superior outcomes
regarding fertility in girls [EL4, adult EL3]. (100%
agreement)
5. Pouch surgery for children with UC should be per-
formed by experienced pediatric or adult surgeons
in high volume centers preferably performing at
least 10 pouches per year. (100% agreement)
Practice Points
1. Crohn disease must be excluded before the time of
surgery, through a diagnostic workup including
ileocolonoscopy, gastroscopy, and small bowel
imaging, before colectomy, as clinical status
allows. (100% agreement)
2. Functional outcomes and surgical complications are
comparable after hand-sewn and stapled IPAA. The
length of remaining anorectal mucosa between the
dentate line and the anastomosis should not exceed
2 cm, regardless of anastomotic technique. (100%
agreement)
3. IPAA without a covering loop ileostomy (ie, 1-stage
procedure) may be considered in selected children
with mild disease and good nutritional status with-
out anti-TNF or steroid treatment, provided that no
technical difficulties or anastomotic tension occur
during surgery; however, the final choice of the
surgical approach should be individualized. (98%
agreement)
4. There is no published evidence on whether post-
poning pouch surgery after subtotal colectomy, for
example, until after puberty, influences long-term
outcomes after IPAA. If pouch surgery is delayed, a
strategy to maintain the rectal stump free of inflam-
mation should be discussed, based on topical treat-
ment. (100% agreement)
5. The role of ileorectal anastomosis (IRA) remains
controversial. It may be offered to selected female
patients, who are particularly concerned about the
risk of reduced fertility associated with IPAA. Infor-
mation on higher failure rate and the need for
lifelong cancer surveillance should be provided.
(98% agreement)
6. Treatment with steroids (prednisolone >0.25 mg 
kg1 day1 or >20 mg/day) is associated with an
increased risk of surgical complications, whereas
thiopurines and calcineurin inhibitors are not. There
are insufficient data regarding vedolizumab. Anti-
TNF increases the surgical risk in Crohn disease and
according to the precautionary principle, colectomy
should be preferably performed 4 to 6 weeks after
the last IFX infusion if it can be safely postponed.
(93% agreement)
Surgery for pediatric UC may require up to 3-staged proce-
dures—first stage, subtotal colectomy with end-ileostomy; second
stage, restorative procto-colectomy with ileal pouch-anal anasto-
mosis or ileo-rectal anastomosis (with or without covering ileost-
omy); third stage, closure of the covering ileostomy. The decision
concerning the best combination of procedures is dictated by the
clinical status of the patient. Restorative procto-colectomy and
IPAA/IRA with covering ileostomy can be performed as a com-
bined first stage for most ‘‘ambulatory’’ elective UC cases.
The covering ileostomy is reversed several months later after
confirmed healing of the pouch (299–303). Three-stage surgery
(subtotal colectomy and ileostomy first) is recommended for
ASC, for example, where the pre-operative PUCAI is >45, or in
those on high-dose pre-operative steroids (prednisolone
>0.20 mg  kg1  day1) (36,301). Although single-stage restor-
ative procto-colectomy IPAA without a covering ileostomy was
not associated with increased anastomotic complications in some
retrospective pediatric series (300,304–306), this cannot be recom-
mended before more studies are available given the retrospective
design of the studies and the inherent confounding by indication
bias.
Emergency surgery for ASC is an initial subtotal colectomy
(leaving a rectal stump) with end-ileostomy formation only. Crea-
tion of IPAA/IRA should be deferred until the clinical status of the
patient has normalized, followed by stoma closure as the third stage.
Laparoscopic colectomy/ileostomy for both ASC and ambulatory
UC is safe and feasible in experienced hands also in children
(36,307). The PUCAI has been reported in a retrospective analysis
to be a useful tool when considering 1- versus 2- versus 3-stage
procedures for pediatric UC (36).
As significant complication rates are reported after colect-
omy for both ASC and ambulatory UC in children, in particular
infectious and thromboembolic events (8,308), peri-operative anti-
biotic and thromboembolism prophylaxis should be routine. The
rectal stump can be fashioned as a mucous fistula (open or within
the subcutaneous tissue) if there is significant proctitis. A more
commonly used alternative is to close the rectal stump within the
abdomen and place a temporary trans-anal drain (309). Length of
hospital stay, short-term surgical complications and functional
outcomes seem similar after open and laparoscopic procedures
(300,310–312).
Steroid treatment, hypoalbuminemia and malnutrition
are also associated with increased surgical complication rates
(313). In ASC, children are likely to have been on recent steroid
therapy and may be in a relatively poor nutritional state,
but surgery when needed should not be delayed to correct this.
Thiopurine and calcineurin inhibitors were not associated
with postoperative surgical complications (313–315), while
current retrospective pediatric data on anti-TNF regimens are
controversial (313,314,316). Meta-analysis of adult data shows
an increased risk of surgical complications in patients who had
been on pre-operative anti-TNF therapy in CD but not in UC
(317,318).
According to a meta-analysis of 5 pediatric studies (306
patients), straight ileo-anal anastomosis (SIAA) was associated with
a higher failure rate (15% vs 8%) and perianal sepsis (20% vs 10%),
as well as a higher stooling frequency as compared with a J pouch
ileo-anal anastomosis (JPAA) (319). A more recent multicenter
study, including 112 children with SIAA, and 91 with JPAA,
reported comparable postoperative complication rates (320). Both
day-time and night-time stooling frequency were higher after SIAA,
although the difference became less apparent by 2 years (mean 24
hours stooling frequency 8.4 vs 6.2 at 2 years). This difference may
still be clinically important, because quality of life in children after
restorative proctocolectomy is inversely associated with stooling
frequency (302).
JPAA, on the other hand, carries a risk of pouchitis, which
clearly exceeds the incidence of enteritis following SIAA (49% vs
24%, OR 4.5; see henceforth detailed chapter on the pouch) (320).
Surgical complications and functional outcomes are comparable
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after hand-sewn or stapled J-pouch anastomosis. For example, in 1
series, stool frequency was 4 per day after both techniques
(299,321,322). A common complication of stapled IAA is, how-
ever, an undesirably long rectal stump with excessive remaining
anorectal mucosa above the dentate line (>2 cm). Chronic inflam-
mation of the rectal mucosal remnant is called ‘‘cuffitis’’ and
discussed further below. One study reported a lower rate of small
bowel obstruction during 4 post-operative years after laparoscopic
IPAA compared to open procedures (310), while no difference was
found in another (300).
In those undergoing IPAA, the diagnosis of UC may change
to CD; 15% in adult series (299,302,303,323) and 11 of 128
children (9%) in a recent multicenter pediatric study from the
Paediatric IBD Porto group of ESPGHAN (324,325). Three-
stage IPAA has been used to reduce these complications in
children with IBDU. Histology of a colectomy specimen or
pre-operative diagnosis of IBDU, however, poorly predicts the
long-term outcomes of IPAA in adults with UC (326,327). In
most studies, the incidence of pouchitis and post-operative diag-
nosis of CD is similar after IPAA in patients with UC and IBDU
(321). There is no published evidence on whether postponing
pouch surgery after subtotal colectomy for an extended period
influences the rate of complications or long-term outcome
after IPAA. Overall, results from pediatric series of IPAA in
terms of later pouch abandonment (<15% at median 10–20 years
follow-up) are similar to adult reports, albeit with shorter
length of follow-up in most series (300,302,328). A multicenter,
retrospective study from the Paediatric IBD Porto Group of
ESPGHAN included 129 children who underwent IPAA, showed
an increased rate of surgical complications in children undergoing
colectomy under the age of 10 years but there was no difference in
complications rate whether the pouch surgery was delayed or not
(324).
While IPAA has been shown to reduce female fecundity and
fertility in adult studies (e.g. reduction of fertility rate by 52%
among women aged 15 to 44 years (323)), most used the non-
stringent definition of inability to become pregnant within 1-year
of intent (322,323). This should be discussed with female
patients and their family before any surgical procedures. Laparo-
scopic IPAA, as is increasingly performed, may ameliorate the
risk of subfertility due to reduced adhesion formation,
pelvic scarring and Fallopian tube obstruction (329–331). In 1
adult series, spontaneous pregnancy rate was higher after
laparoscopic IPAA (70%) compared to open IPAA (39%,
P¼ 0.023) among 50 women who attempted to conceive (326).
Fertility is also much better preserved after IRA (300). Fecundity
remained similar to the general population after IRA, but dropped
to 54% after IPAA among women with familial adenomatous
polyposis (327). In a recent follow-up study of 343 adults with
UC, 10- and 20-year IRA failure rate was 27% and 40%, respec-
tively (328). Secondary proctectomy was required for refractory
proctitis (66%), dysplasia (11%) and for cancer (10%) (332). At the
end of the follow-up, 18% had undergone secondary IPAA and
13% had permanent ileostomy. Although fecal continence and
stooling frequency is better preserved after IRA compared to
IPAA, most patients require anti-inflammatory medication and
urgency rate is higher, while quality of life similar to that after
IPAA (328).
Data from the Porto group of ESPGHAN suggest that the
experience of the surgeon is associated with the likelihood of
development of chronic pouchitis; (15%) in surgeons with 10 sur-
rgeries/year versus (41%) in surgeons with<10 per year, P¼ 0.013
(325). This is in line with a large study from the UK showing the
pouch outcome was superior if done in centers performing at least 9
to 10 procedures annually (333).
Pouchitis and Cuffitis
Recommendations
1. Pouchoscopy with mucosal biopsies should be per-
formed at the first suspected episode of pouchitis
[EL3, adult EL3]. (95% agreement)
2. A 14-day course of ciprofloxacin and/or metronida-
zole is recommended as first-line therapy for pou-
chitis while the former may be more effective [EL5,
adult EL1]. (100% agreement)
3. Combined metronidazole and ciprofloxacin or oral/
topical budesonide can be used in persistent cases
[EL5, adult EL2]. (98% agreement)
4. In recurrent and/or chronic pouchitis, VSL#3 is
recommended for maintaining remission [EL5, adult
EL1]. (98% agreement)
5. Topical mesalamine is recommended for treating
cuffitis [EL 5, adult EL4]. (100% agreement)
Practice Points
1. A clinically useful categorization of pouchitis is ‘‘anti-
biotic-responsive’’ (ie, infrequent episodes (<4 per
year) each with a rapid response to a 2-week course
of a single antibiotic, ‘‘antibiotic-dependent’’ (ie,
frequent episodes (4 per year) or persistent symp-
toms which require long-term antibiotic therapy to
maintain remission) and ‘‘antibiotic-refractory’’ (ie,
failure to respond to a 4-week course of antibiotics,
necessitating an alternative therapy of 4 weeks or
longer). Duration of pouchitis can be categorized as
acute (<4 weeks) or chronic (4 weeks) and fre-
quency may be described as infrequent, relapsing,
or continuous. (100% agreement)
2. In chronic, recurrent or refractory pouchitis-like
symptoms, other diagnoses, such as cuffitis, missed
Crohn disease, anastomotic ulcer, irritable pouch
syndrome, infectious pouchitis, and anastomotic
stenosis, should be excluded. (100% agreement)
3. Fecal calprotectin may be used to assess pouch
inflammation to minimize repeated pouchoscopies
in recurrent pouchitis and to monitor response to
treatment. Calprotectin >300 mg/g is suggestive of
pouchitis while lower levels do not preclude pou-
chitis (57% sensitivity, 92% specificity). (95%
agreement)
4. The common antibiotic dosing strategies for pou-
chitis are ciprofloxacin (30 mg  kg1 day1 up to
1 g/day in 2 divided doses) and/or metronidazole
(20–30 mg  kg1 day1 in 3 divided doses up to
1.5 g/day) for 14 days. (98% agreement)
5. VSL#3 can be used once daily at an age- or weight-
dependent dose (Table 5). (95% agreement)
6. VSL#3 may be also effective for preventing the first
episode of pouchitis, but this is not justified since
many children will never develop pouchitis. (100%
agreement)
7. Thiopurines may be considered in refractory pou-
chitis, not responding to antibiotic therapy or in the
presence of budesonide dependence, despite the
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lack of good evidence. The effectiveness of IFX for
this indication has been demonstrated only in adult
case series with a response rate of 50%. (98%
agreement)
Pouchitis, a non-specific and idiopathic inflammation of the
ileal reservoir, is the most common complication of IPAA, occur-
ring in 24% to 67% of pediatric UC patients (299,300,302,320,
323,334–337). A recent multicenter, retrospective cohort study
from the Paediatric IBD Porto Group of ESPGHAN included
129 children who underwent IPAA (93% UC and 7% IBDU)
and showed that 86 children (67%) developed pouchitis during
follow-up (325). In 33 (26%) the pouchitis was chronic, 10 of whom
(8%) had Crohn-like disease of the pouch. Median time from pouch
formation to the first episode of pouchitis was 10.5 months (IQR 6–
22); in 54% of cases the first episode occurred within 1 year. In an
older cohort of 399 UC children with a mean age of 18	 3 years at
colectomy, 121 (36%) had at least 1 episode of acute pouchitis, and
29 (9%) pouch failure (300). Pouch type, age, and operative
technique had no impact on whether patients developed pouchitis.
Symptoms and severity of pouchitis vary, but typically
include increased stool frequency and urgency, tenesmus, inconti-
nence, abdominal pain, and rectal bleeding (338). Cuffitis, residual
rectal cuff inflammation, may cause symptoms similar to those of
pouchitis, especially bleeding. The cuff is the remaining rectal
mucosa between the dentate line and the anastomosis after restor-
ative procto-colectomy. Symptoms of pouch dysfunction in patients
with IPAA may be caused by conditions other than pouchitis,
including CD of the pouch, anastomotic ulcer or stenosis. In
children, the occurrence of terminal ileitis, or ‘‘pre-pouch ileitis,’’
has also been reported (339), and does not necessarily confirm the
diagnosis of CD if it involves only mild inflammation in a short
segment. Other differential diagnoses include ischemia and, rarely,
infections such as CMV and C difficile. A diagnosis of irritable
pouch syndrome is suspected when symptoms are present without
endoscopic inflammation (340). Thus, endoscopic and histological
evaluation of the pouch should be performed at the first episode of
pouchitis and periodically thereafter.
Endoscopic features of pouchitis may include hyperemia,
diminished vascular pattern, friability, hemorrhage, and ulcers.
Abnormalities may be focal or diffuse, and unlike in UC, they
may be discontinuous. Often, they are more severe in the distal
compared to the proximal pouch (341–343). Mucosal biopsies
typically demonstrate partial to complete villous blunting with crypt
hyperplasia and increased mononuclear inflammatory cells and
eosinophils in the lamina propria, crypt abscesses, and ulcerations.
Mucosal biopsies should be obtained from the pouch and from the
afferent ileal loop, but not from the staple line, as erosions and/or
ulcers along the staple line do not necessarily indicate pouchitis (344).
Two main scoring systems exist for the diagnosis of pouchitis
but their utility in clinical practice is limited as they await further
validation to associate the scores with clinical outcomes (345,346).
The Pouchitis Disease Activity Index (PDAI) evaluates symptoms,
endoscopic findings, and histological patterns in a composite score,
with a score of 7 indicating pouchitis (347). The Pouchitis
Activity Score (PAS) incorporates similar elements to the PDAI
and a score >13 is suggestive of pouchitis (348). A modified PDAI
(mPDAI), omits the histology component (349).
Several variables may predict the risk of pouchitis. A small
pediatric study reported that the only predictive factor associated
with risk of pouchitis was a higher PUCAI score at the time of
diagnosis (337). As discussed above, data suggest that the surgeon’s
experience is associated with risk for pouchitis (325). Chronic
pouchitis was also associated with Ashkenazi Jewish ethnicity,
while any-pouchitis was associated with age at diagnosis and longer
disease duration. Several adult studies have reported an increased
incidence of pouchitis in patients with a younger age at onset,
backwash ileitis, PSC, extensive colonic disease, positive pANCA,
preoperative steroid use, being a non-smoker, and carriage of
genetic polymorphisms in NOD2/CARD15, which is more preva-
lent in Ashkenazi Jews (66,350–358).
The probiotic mixture VSL#3 was effective in maintaining
remission in adult patients with chronic pouchitis as shown in 2
double-blind placebo-controlled trials from Italy (359,360). Results
regarding the effectiveness of VSL#3 in preventing the first episode
of pouchitis are more controversial (361,362).
Antibiotic treatment is considered first-line treatment for
pouchitis. Only small placebo-controlled trials have, however, been
conducted to support this practice and none in children (363,364).
Ciprofloxacin may be slightly more effective than metronidazole,
with fewer adverse events. Shen et al have shown the superiority of
ciprofloxacin over metronidazole in inducing remission (365). In
antibiotic-refractory pouchitis, Gionchetti et al used oral budeso-
nide for 8 weeks and achieved remission in 75% of 20 patients
(366,367). A case series of 28 patients with refractory pouchitis
were treated with IFX of whom 88% responded after 10 weeks, and
56% after a median follow-up of 20 months (368); other case series
also support the use of IFX in refractory pouchitis (369,370) as well
as adalimumab (371) and alicaforsen (an inhibitor of intercellular
adhesion molecule-1) enemas (372).
In an open study, topical treatment with metronidazole
induced clinical improvement within a few days without systemic
side effects and with a decrease in concentrations of anaerobic
bacteria (373). Furthermore, uncontrolled studies have suggested
that 5-ASA either as suppositories or enemas may help in the
treatment of pouchitis (374).
OTHER MANAGEMENT CONSIDERATIONS
Extraintestinal Manifestations
Recommendations
1. Treatment of peripheral arthritis should be directed
at inducing remission of the luminal disease [EL4,
adult EL3]; sulfasalazine should be considered as
first-line treatment for peripheral arthritis, followed
by anti-TNF [EL4, adult EL2]. (93% agreement)
2. Transaminases and gGTshould be monitored at least
annually in all UC patients, to screen for PSC and
autoimmune hepatitis [EL4, adult EL4]. (100%
agreement)
3. Chronic elevation of liver enzymes in the presence
of cholestasis, should be investigated with ultra-
sound followed by MR-cholangiopancreatography
(MRCP), in addition to liver biopsy when indicated
(see practice point); endoscopic retrograde cholan-
giopancreatography (ERCP) is recommended for
therapeutic interventions [EL3, adult EL3]. (95%
agreement)
4. Patients with PSC and IBD are at increased risk
for colorectal carcinoma (CRC) and thus annual or
bi-annual surveillance colonoscopy should be initi-
ated from the time of PSC diagnosis. However,
surveillance could be deferred in pre-pubertal
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children while individualizing based on risk factors
(disease duration, family history, severity of the
disease over time, and disease extent), since CRC
is extremely rare under the age of 12 years even in
the presence of PSC. (95% agreement)
Practice Points
1. Acute peripheral arthritis affecting the large joints is
usually associated with active IBD and thus treat-
ment should be directed to the gut. (98% agree-
ment)
2. The diagnosis of axial spondylo-arthritis or sacro-
ileitis is based on typical clinical signs such as pro-
gressive low back pain, gluteal and thigh pain com-
bined with radiological abnormalities (most often
MRI). Treating sacro-ileitis requires close collabora-
tion with a rheumatologist. (100% agreement)
3. If required for the treatment of articular inflamma-
tion, non-steroidal anti-inflammatory drugs may be
used for a short course and at low doses to minimize
the risk of aggravating IBD. (98% agreement)
4. Since some degree of autoimmune hepatits/overlap
syndrome is not uncommon in children with PSC, a
low threshold should be practiced when consider-
ing a liver biopsy in this setup. (95% agreement)
5. No medication has been proven to reduce the time
from PSC diagnosis to liver transplant or the devel-
opment of cholangiocarcinoma. The benefit of urso-
deoxycholic acid remains questionable, and if
used, doses should be preferably low (10–
15 mg  kg1 day1). Alternatively, oral vancomycin
may be considered (usual total daily dose 35 mg/kg
(maximum 1500 mg) divided into 3 times daily), for
12 weeks but long-term data are lacking. (95%
agreement)
6. PSC is a significant risk factor for cholangiocarci-
noma also during childhood. Serial CA19.9 and liver
ultrasound/MRCP testing may thus be considered
every 1 to 2 years to screen for cholangiocarcinoma
but there is no pediatric evidence to support this
practice. (95% agreement)
We would like to refer the reader to comprehensive ECCO
guidelines on extraintestinal manifestations (EIM) and highlight
here only pertinent points common in children (375). Some EIM are
associated with intestinal disease activity (ie, erythema nodosum,
peripheral arthritis), whereas others occur independently (ie, pyo-
derma gangrenosum, uveitis, ankylosing spondylitis, and PSC)
(376). Data from 2 pediatric registries in the USA (377,378) and
1 in Europe (376) indicate that 1 or more EIMs are present at
diagnosis in 6% to 17% % of children with UC, especially those
older than 5 years, with an increase to almost 50% with disease
evolution (379–382), and more so with extensive colitis (378).
Joint disease in IBD may be axial (sacro-ileitis or ankylosing
spondylitis), causing lower back pain or peripheral arthritis, which
is usually acute and self-limiting, seronegative and not deforming.
In children, the prevalence of arthritis seems to be twice as high as
in adults, (377) with a clear female predominance. There are some
concerns about aggravating the bowel disease by using NSAIDs;
however, the risk seems to be low if prescribed for a short course
and at low doses (383). The sulfapyridine component of sulfasa-
lazine has an anti-inflammatory effect on both the colonic mucosa
and the joints (384). MTX is the cornerstone disease-modifying
anti-rheumatic drug in juvenile arthritis (385) but anti-TNF regimes
have emerged in the last 2 decades (386).
PSC is 3 times more likely to occur in UC compared to CD
(378), and is associated with older age in children (378). PSC may
precede the onset of IBD by years but may occur even after
colectomy. The prevalence of PSC in pediatric IBD is 1.6% at
10 years after diagnosis (377), but higher at 3% (387) if systematic
screening tests are performed. In a recent multicenter report of 781
children with PSC (4277 person-years of follow-up), overall event-
free survival was 70% at 5 years and 53% at 10 years but PSC-IBD
was associated with a favorable prognosis; cholangiocarcinoma
occurred in 1% (388).
Being non-invasive, MRCP is the most appropriate imaging
modality for diagnosing PSC in children. A pattern of irregular bile
ducts, with zones of narrowing and dilatation is characteristic of PSC
(389). PSC may progress to liver cirrhosis, ultimately necessitating
liver transplantation. Patients with PSC and UC have a greater risk of
malignancies such as CRC and cholangiocarcinoma (8%–30% of UC
patients with long standing PSC) (390,391). A recent study on the
cancer and mortality in children in Europe has demonstrated several
cases associated with PSC (10), but CRC in UC children younger than
12 years is extremely rare. PSC is associated with more extensive
disease and thus has a greater cancer risk (391) but also with milder
disease course. The higher colectomy rate in these patients is secondary
to dysplasia and CRC. In adults with PSC, ursodeoxycholic acid is
reported to improve abnormal liver tests (392) and to reduce the risk of
CRC (393), although this has not been shown by all (394,395). No
therapy has been shown to reduce time to liver transplantation,
cholangiocarcinoma or death (394,396,397). Recent recommenda-
tions for adult patients suggest ursodeoxycholic acid at a dose of 10
to 15 mg  kg1  day1 and warn against high dose treatment
(>20 mg  kg1  day1), which may increase mortality (394,395,398).
Oral vancomycin may be considered for 12 weeks as it has
been shown to reduce and even normalize serum liver enzymes and
gGT (399–405). Both vancomycin and metronidazole have been
efficacious in recent small studies; however, only patients in the
TABLE 6. Diagnostic workup of very early onset IBD to be adapted
according to the clinical presentation (see text)
Basic immune workup Examples
Complete blood count Neutropenia, lymphocytopenia,
thrombocytopenia
Lymphocyte subset T-/B-cell defects, regulatory T cell
defects (FOXP3, CD25)
IgG-A-M-E SCID, CVID, B-cell defects,
agammaglobulinaemia, hyper-IgM/
hyper-IgE syndrome
Oxidative burst CGD
Functional tests IL10-axis (LPS-IL10 stimulation);
XIAP-nod-axis (MDP stimulation);
apoptosis tests (XIAP)
Genetic testing
Candidate gene approach Suspected defect or confirmation of
identified defect
Gene panel Unclear diagnosis
Whole exome or genome
sequencing
Research protocol for search of new
mutations
CGD ¼ chronic granulomatous disease; CVID ¼ common variable
immunodeficiency; IL ¼ interleukin; SCID ¼ severe combined immunode-
ficiency; XIAP ¼ X-linked inhibitor of apoptosis protein.
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vancomycin groups reached the primary endpoint, and with fewer
adverse effects (403). Oral vancomycin re-treatment when needed
has been associated with a rise in T regulatory cells (Treg) and
normalization of liver function tests (406).
Older age at PSC diagnosis increases the risk of colonic
neoplasia (407). Targeted biopsies aimed at abnormal areas identi-
fied by newer colonoscopic techniques (chromoendoscopy, confo-
cal microendoscopy) should be preferred (408). The optimal
follow-up method is still debatable (409).
Nutrition, Growth, and Bone Health
Practice Points
1. High intake of red or processed meat, protein,
alcoholic beverages, sulfur, and sulfates have been
associated with disease exacerbations. Due to the
lack of solid evidence, exclusion diets, however,
should not be used to induce or maintain remission
in pediatric UC, and could lead to nutritional defi-
ciencies. (100% agreement)
2. DEXA (corrected for height and age to produce age-
and sex-matched z scores (410)) should be consid-
ered in high-risk patients such as those with severe
disease, prolonged malnutrition, amenorrhea,
delayed puberty, and/or steroid dependency.
(98% agreement)
3. Promoting mucosal healing, adequate nutrition,
weight-bearing exercise, avoiding smoking, and
steroid-sparing strategies should be employed to
facilitate bone health. The rare use of bisphospho-
nates should be reserved to those with pathological
fractures, in consultation with a pediatric bone spe-
cialist. (100% agreement)
4. Growth impairment is rare in children with UC who
are not steroid-dependent. Therefore, Crohn colitis
or primary growth hormone deficiency should be
considered when significant growth impairment is
present. (100% agreement)
5. Vitamin D should be supplemented if 25-OH vita-
min D is <50 nmol/L, regardless of steroid use.
(93% agreement)
6. There are different strategies in treating vitamin D
deficiency in addition to daily treatment (>2000 IU/
day). A commonly applied strategy is to prescribe a
‘‘loading dose’’ (50,000 IU of vitamin D3 orally once
weekly for 2 to 3 months, or 3 times weekly for 1
month). Single high-dose oral vitamin D3 300,000
to 500,000 IU (ie, stoss dosing) has been reported
(411) to be effective and safe. (98% agreement)
While nutritional deficiencies can develop quickly during
periods of active UC (412), normal growth is maintained in >95%
of children with UC who are not steroid dependent (413–415). A
more detailed review of all nutritional issues in children with IBD can
be found in the recently published guideline from the Paediatric IBD
Porto group of ESPGHAN (416). Patients with active UC often
reduce fiber in their diets without supportive evidence. Corn and corn
products, nuts, milk, and bran were avoided by>20% of UC patients
(417). Soluble fiber is, however, the best way to generate short-chain
fatty acids such as butyrate, which has anti-inflammatory effects
(418). In addition, many UC patients avoided tomato, dairy products,
chocolate, wheat, tomato sauces, and fruit juice (417), but there is no
nutritional intervention clearly supported in UC and the reader is
referred to an excellent recent summary on the topic (418).
Peak bone mass attained during adolescence is the most
important determinant of lifelong skeletal health. Some osteopenia
is present in up to 22% of UC children (419), but severe osteopenia
is only present in 3% to 6% in UC, as compared with 12% to 18% in
CD (420–422). Nutritional status seems to have a greater impact on
bone status than corticosteroid therapy (423). Children with IBD are
at particularly risk for vitamin D deficiency, but this was not found
to be directly associated with osteopenia (424). Nonetheless, vita-
min D deficiency should be treated especially in children with
decreased bone mineral density. A recent meta-analysis showed that
low vitamin D is associated with a more active disease (425). Age-
appropriate nutrition support, weight-bearing exercise, and ade-
quate disease control using steroid-sparing strategies (410,421,426)
have been suggested as means to improve bone formation but
without supportive evidence. Indeed, a prospective study that
followed 58 children with CD for 2 years did not show significant
improvement in bone mineral density despite increased height z
score and reduced disease activity (421).
The most important determinant of treating osteopenia,
besides avoiding steroids, is efficient treatment aiming at mucosal
healing since osteopenia may typically be a consequence of pro-
inflammatory cytokines (427). Indeed, interventions that lead to
mucosal healing such as anti-TNF therapy and exclusive enteral
nutrition showed rapid improvement of serum bone markers in
children with CD (428–432). Bisphosphonates are effective to
improve bone mineral density in IBD but pediatric use should be
reserved for extreme circumstances, typically when pathological
fractures are present, an uncommon situation in UC.
Psychosocial Support, Adherence to Therapy,
and Transitional Care
Recommendations
1. Adolescents should be included in transition to adult
care programs, which can be adapted according to
the local organization of the pediatric and adult
facilities [EL4]. (100% agreement)
Practice Points
1. Paediatric IBD centers should offer psychological
support according to local resources. (100%
agreement)
2. Adherence should be regularly evaluated by patient
interviews, drug monitoring (eg, serum drug level),
and prescription refill rates. (100% agreement)
3. Adherence may be improved by providing compre-
hensive information regarding the prescribed medi-
cation, keeping the pill burden as low as possible,
using single daily dosage when possible, utilizing
electronic reminders and providing pill boxes.
(100% agreement)
Several systematic reviews concluded that adolescents with
IBD, especially boys, have reduced health-related quality of life,
including anxiety, depression, social problems, and low self-esteem
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(433–436). The altered quality of life of children with IBD can
affect the entire family, who often lack the appropriate strategies to
deal with this complicated reality (437). The rate of depression may
be as high as 25% and it is often under-recognized both by parents
and health care professionals. Anxiety and depression appear to be
risk factors for early recurrence of the disease and adversely affect
the disease course but may also commonly be a reactive response to
active disease (438). Cognitive behavioral therapy has been shown
to be especially effective in improving depressive symptoms and
functioning in children with IBD (439).
Non-adherence in IBD is reported in 50% to 66% of children
(433,440), especially during adolescence. Pediatric-specific bar-
riers include fear of adverse events of medication, feeling that the
disease is inactive, belief that the medication is not working, >1
daily medication, forgetting, interfering with other activities, diffi-
culty in swallowing pills (441), lack of motivation, and parent-child
conflict (442).
Transition is defined as the planned move of adolescents and
young adults with long-term physical conditions from child-centered
to adult-orientated healthcare. The optimal timing of transition from
pediatric to adult management of UC has to be decided on an
individual basis by a joint team of pediatric and adult gastroenter-
ologists (443). Several suggestions for transition programs have been
published, but none has been formally evaluated (444). The transition
period usually starts from the age of 14 to 18 years depending on the
development of the patient and availability of qualified pediatric and
adult gastroenterologists. The time of transition should be individu-
ally adapted according to the psychosocial readiness. Whenever
feasible, at least 1 joint clinic with both the pediatric and the adult
gastroenterologist is recommended during the transition process. The
adolescent should be encouraged to assume increasing responsibility
for treatment and to visit the clinic room at least once without being
accompanied by the parents. The ECCO topical review on transition
to adult care addresses in detail all aspects related to the steps to be
followed during transition (445).
Very Early-Onset Inflammatory Bowel Disease
Presenting As Colitis
Practice Points
1. In infants younger than 2 years, allergic colitis,
immunological disorders and monogenic forms of
colitis should be excluded. (100% agreement)
2. Unusual disease evolution, history of recurrent infec-
tions, HLH, and non-response to multiple IBD med-
ications may indicate an underlying genetic defect
which should prompt genetic and/or immunologi-
cal analyses at any age during childhood (Table 6).
(100% agreement)
The colitis phenotype is the most common in the VEOIBD
group (6 years of age and younger) (446), and even Crohn disease
frequently resembles UC. Therefore, the term IBDU rather than UC
may be more appropriate in this earlier age group, reported in 34%
and even 71% of very young children (447,448). The differential
diagnostic spectrum for this age group is challenging (448,449)
since the colitis may be caused by various immunological disorders:
classical immune defects (such as combined immune-deficiencies),
subtle immune defects or defects of the regulation of immune
responses due to a monogenetic disorder including defects in
interleukin (IL)10-signaling, X-linked inhibitor of apoptosis protein
(XIAP) deficiency, defective neutrophil function and many others
(Table 6) (449). Since no specific biological test confirms allergic
colitis, only a successful trial of elimination diet is useful diagnos-
tically (450) and may be proposed according to the clinical context
especially in those younger than 1 year.
A large percentage of children with IBD developing before
age 6 years present with relatively typical colitis, including mild
disease which can be easily managed with 5-ASA (451). Many
monogenic forms of VEOIBD may, however, initially appear as
typical polygenic IBD but then prove resistant to standard therapy
(448,449). Over 50 different monogenetic defects causing an IBD-
like disorder have been described. A complete review of the genetic
workup of VEOIBD and treatments is beyond the scope of these
guidelines and the reader is referred to a previous comprehensive
review (449). Briefly, appearance of perianal disease with skin
folliculitis during the first few months of life is a strong indicator of
a defect in the IL10 axis (452–454). Repeated bacterial and fungal
infections orientate toward defective neutrophil functions, (eg,
chronic granulomatous disease (455,456)). Recurrent skin infec-
tions, and EBV or CMV-induced HLH may indicate the presence of
XIAP-defect (457). This X-linked defect can affect boys and in rare
cases also girls (458). The presence of multiple intestinal atresia, or
evidence of increased rate of epithelial cell apoptosis on small
bowel biopsy may hint toward TTC7A, especially when observed in
the presence of low IgG levels, T- and B-cell lymphopenia and mild
reduction in NK cells (459–461). Woollen, fragile hair, and facial
abnormalities (small chin, broad flat nasal bridge, and prominent
forehead), immune defects, liver disease, and colitis (referred to as
trichohepatoenteric syndrome or phenotypic diarrhea) may be due
to mutation in SCIVL2 (462) or TTC37 (463). If signs of autoim-
munity are associated with intestinal inflammation with high rates
of epithelial cell apoptosis, IPEX-syndrome or IPEX-like disorders
should be considered (464–467).
If the molecular defect is caused by a mutation affecting
predominantly immunological cells (eg, IL10 signaling defects,
XIAP and chronic granulomatous disease), hematopoietic stem cell
transplantation may be curative (452,453,458,468). Inhibition with
IL1-antagonists may be a way to stabilize patients with IL10
signaling defects while awaiting hematopoietic stem cell transplan-
tation (HSCT), but more confirmation is required before this can be
utilized in clinical practice (469). Early HSCT improves life
expectancy of IL10-deficient patients since they are at risk for
developing lymphoma (470). HSCT is not always the ultimate
treatment option, as shown in patients with TTC7A mutations,
which involve the epithelial gut barrier rather than immunological
cells. This highlights the importance of a rapid and precise molecu-
lar diagnosis in children with colitis starting early in life.
SYNTHESIS AND SUMMARY
This Part 1 of the pediatric UC guidlines yielded 40 formal
recommendations and 86 practice points along with practical tables
and figures, based on systematic review of the literature. Guidance
for the management of pediatric UC is summarized in algorithms to
be used in conjunction with reading this document (Figs. 2 and 3).
The goal of treatment in active UC should be complete clinical
remission (PUCAI < 10 points), and usually this can be assessed
without the need for endoscopic verification. Nonetheless,20% of
children in clinical remission can still have endoscopic inflamma-
tion, and thus calprotectin may aid in selecting those who require
endoscopic evaluation to ensure mucosal healing has been
achieved. The choice of treatment in adults is a factor of both
the disease severity and disease extent (15,16), but since limited
distal disease is uncommon in children, pediatric treatment strategy
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mainly depends on disease severity. Mesalamine regimes are con-
sidered first line for inducing and maintaining remission of mild-to-
moderate UC. Non-response to oral mesalamine may be treated with
the addition of mesalamine enemas and/or switching to locally active
steroids, with budesonide-MMX only in left-sided colitis. In ambu-
latory children with moderate-to-severe UC, or in those with mild to
moderate disease, who have failed optimized mesalamine therapy,
oral steroids should be used, but only as induction agents. If the
patient does not clearly respond to oral steroids within 1 to 2 weeks,
consider admission for intravenous corticosteroids (see Part 2 of these
guidelines). In refractory non-severe cases, an alternative to admis-
sion may include outpatient treatment with IFX (especially in those
who failed thiopurines and mesalamine); in selected patients, oral
tacrolimus may be considered.
Patients who received intravenous corticosteroids should
be usually weaned to thiopurines. Almost all children with UC must
be treated with a maintenance therapy indefinitely. Anti-TNF is indi-
cated for non-response to corticosteroids, and in loss of response or
intolerance to mesalamine and thiopurines. Patients needing anti-TNF
induction should continue this therapy and if thiopurine-naı¨ve, may be
subsequently stepped down to thiopurines after a period of 6 to
12 months of deep remission. Golimumab or adalimumab should be
considered in secondary loss of response to IFX due to antibody
formation. Vedolizumab is a valid option in primary non-response
to anti-TNF, in secondary loss of response in the presence of adequate
drug level, and in anti-TNF related adverse events, such as refractory
psoriasis. Endoscopic evaluation is recommended before any signifi-
cant treatment change. Finally, colectomy is always a viable option,
which must be discussed whenever treatment escalation is considered.
These clinical management guidelines were developed to
assist practitioners at all levels of health care, while recognizing that
each patient is unique. The recommendations may, thus, be subject
to local practice patterns, and serve merely as a general framework
for the management of UC in children. The development of the
guidelines should now be followed by dissemination of the infor-
mation to clinical practice.
DISCLAIMER
ESPGHAN and ECCO are not responsible for the practices
of physicians and provide guidelines and position papers as indi-
cators of best practice only. Diagnosis and treatment is at the
discretion of physicians.
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APPENDIX 1: THE PEDIATRIC ULCERATIVE
COLITIS ACTIVITY INDEX (PUCAI)
Item Points
1. Abdominal pain
No pain 0
Pain can be ignored 5
Pain cannot be ignored 10
2. Rectal bleeding
None 0
Small amount only, in less than 50% of stools 10
Small amount with most stools 20
Large amount (>50% of the stool content) 30
3. Stool consistency of most stools
Formed 0
Partially formed 5
Completely unformed 10
4. Number of stools per 24 hours
0–2 0
3–5 5
6–8 10
>8 15
5. Nocturnal stools (any episode causing wakening)
No 0
Yes 10
6. Activity level
No limitation of activity 0
Occasional limitation of activity 5
Severe restricted activity 10
Sum of PUCAI (0–85)
For user’s guide and cutoff values for response, remission, mild, moder-
ate, and severe disease activity, refer to the original study (39).
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